var title_f22_35_23088="L femur with Paget disease of bone";
var content_f22_35_23088=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F66075&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F66075&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left femur with Paget disease of bone",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 361px; height: 540px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is a radiograph of the&nbsp;left femur. Note the advancing lytic lesion, the thickening of the femoral diaphysis and the grossly abnormal remodeling evident there.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Margaret Seton, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_35_23088=[""].join("\n");
var outline_f22_35_23088=null;
var title_f22_35_23089="Unstable comminuted proximal phalangeal shaft fracture";
var content_f22_35_23089=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F67867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F67867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Unstable comminuted proximal phalangeal shaft fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 274px; height: 477px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Unstable fractures need to be reduced and the stability of the reduction assessed by x-ray.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_35_23089=[""].join("\n");
var outline_f22_35_23089=null;
var title_f22_35_23090="Normal thromboelastography and parameters";
var content_f22_35_23090=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F58281%7ESURG%2F80926&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F58281%7ESURG%2F80926&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 613px\">",
"   <div class=\"ttl\">",
"    Normal thromboelastography and parameters",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 593px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal citrated rapid TEG tracing with normal ACT, R time, K time, alpha angle, MA, G, and LY30.",
"    <div class=\"footnotes\">",
"     R (reaction time): time from sample placement or activation until the tracing amplitude reaches 2 mm; K (clot formation time): time elapsed between the R-time and the point where the tracing amplitude reaches 20 mm; alpha angle: angle between the middle line of the tracing and a tangential line to the developing \"body\" of the tracing; MA (maximal amplitude): the maximal amplitude reached after clot initiation; G: a calculated measure of total clot strength based on amplitude; LY30: the amount of clot lysis detected 30 minutes after the maximal amplitute (MA) is reached; SP (split point): time from sample placement (or activation with an exogenous procoagulant) until the earliest detectable resistance.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 613px\">",
"   <div class=\"ttl\">",
"    Thrombocytopenia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 593px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Citrated rapid-TEG reflecting thrombocytopenia.The red line is a normal tracing.",
"    <br>",
"     This study shows a normal ACT, R time, K time, and LY30; low alpha angle, MA, and G, reflecting platelet hypocoagulability.",
"     <div class=\"footnotes\">",
"      R (reaction time): time from sample placement or activation until the tracing amplitude reaches 2 mm; K (clot formation time): time elapsed between the R-time and the point where the tracing amplitude reaches 20 mm; alpha angle: angle between the middle line of the tracing and a tangential line to the developing \"body\" of the tracing; MA (maximal amplitude): the maximal amplitude reached after clot initiation; G: a calculated measure of total clot strength based on amplitude; LY30: the amount of clot lysis detected 30 minutes after the maximal amplitute (MA) is reached; SP (split point): time from sample placement (or activation with an exogenous procoagulant) until the earliest detectable resistance.",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_35_23090=[""].join("\n");
var outline_f22_35_23090=null;
var title_f22_35_23091="Electron micrograph of a normal glomerulus";
var content_f22_35_23091=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F50018&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F50018&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Electron micrograph of a normal glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electron micrograph of a normal glomerular capillary loop showing the fenestrated endothelial cell (Endo), the glomerular basement membrane (GBM), and the epithelial cells with its interdigitating foot processes (arrow). The GBM is thin, and no electron dense deposits are present. Two normal platelets are seen in the capillary lumen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_35_23091=[""].join("\n");
var outline_f22_35_23091=null;
var title_f22_35_23092="Phenoxybenzamine: Patient drug information";
var content_f22_35_23092=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Phenoxybenzamine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/0/38916?source=see_link\">",
"     see \"Phenoxybenzamine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/58/19364?source=see_link\">",
"     see \"Phenoxybenzamine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F209081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dibenzyline&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692015",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat pheochromocytoma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702727",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to phenoxybenzamine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose stuffiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12095 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-593C6D74E4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_35_23092=[""].join("\n");
var outline_f22_35_23092=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209081\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020571\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020573\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020572\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020577\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020578\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020580\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020575\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020576\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020581\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020582\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/0/38916?source=related_link\">",
"      Phenoxybenzamine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/58/19364?source=related_link\">",
"      Phenoxybenzamine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_35_23093="TDE constriction v restriction";
var content_f22_35_23093=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F58771&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F58771&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 481px\">",
"   <div class=\"ttl\">",
"    Tissue Doppler echocardiography in constrictive pericarditis and restrictive cardiomyopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 461px; height: 328px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shown are examples of echocardiograms from a normal subject, a patient with a restrictive cardiomyopathy and a patients with constrictive pericarditis. Panel A shows the posterior left ventricular wall on an M-mode echocardiogram, panel B is the mitral inflow velocity obtained from Doppler echocardiogram, and panel C is from tissue Doppler echocardiogram. The Doppler echocardiogram from the mitral valve inflow records a deep narrow E wave and diminutive A wave in both constrictive pericarditis and restrictive cardiomyopathy. Tissue Doppler records a diminutive myocardial velocity (E') in restrictive cardiomyopathy (arrow), but E' is similar to E in constrictive pericarditis. Tissue Doppler is thus a powerful means to distinguish between these two disease entities.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ralph Shabeti, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_35_23093=[""].join("\n");
var outline_f22_35_23093=null;
var title_f22_35_23094="Menorrhagia (excessive menstrual bleeding)";
var content_f22_35_23094=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"topicTitle\">",
"   Patient information: Menorrhagia (excessive menstrual bleeding) (Beyond the Basics)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/35/23094/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/35/23094/contributors\">",
"     Howard A Zacur, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/35/23094/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/35/23094/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/35/23094/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/35/23094/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/35/23094/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a normal menstrual cycle, a woman loses an average of 2 to 3 tablespoons (35 to 40 milliliters) of blood over three to seven days. However, some women lose a lot more blood. Menorrhagia is the medical term for heavy or prolonged menstrual bleeding. Most women have a menstrual period every 25 to 35 days; the average is every 28 days.",
"   </p>",
"   <p>",
"    Women who lose 5 to 6 tablespoons (about 80 milliliters) of blood or more during their menstrual period are said to have menorrhagia. Losing a lot of blood during the menstrual period can cause medical problems like anemia (low number of red blood cells).",
"   </p>",
"   <p>",
"    There are several treatments for heavy bleeding. More detailed information about heavy menstrual bleeding is available by subscription. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/41/20122?source=see_link\">",
"     \"Chronic menorrhagia or anovulatory uterine bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MENORRHAGIA CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common causes of excessive menstrual bleeding are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Not ovulating once per month (called anovulation)",
"     </li>",
"     <li>",
"      Having abnormal growths in the uterus, such as polyps or fibroids",
"     </li>",
"     <li>",
"      Having a condition that increases bleeding throughout the body",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Anovulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anovulation occurs when your ovaries do not produce and release an egg (ovulate) once per month. This causes your menstrual period to be irregular or absent. Anovulation is common in adolescents and in women who are near menopause. Women with polycystic ovary syndrome (PCOS) often do not ovulate regularly. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?29/12/29891?source=see_link\">",
"     \"Patient information: Absent or irregular periods (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Growths in the uterus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noncancerous growths in the uterus can cause heavy menstrual bleeding. The most common noncancerous growths are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Polyps, which are small, grape-like growths of the lining of the uterus",
"     </li>",
"     <li>",
"      Fibroids (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?20/20/20804?source=see_link\">",
"       \"Patient information: Uterine fibroids (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Overgrowth of the lining of the uterus (called endometrial hyperplasia, which can be a precursor to uterine cancer)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Bleeding tendency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with certain bleeding conditions or who take certain medicines can have heavy menstrual bleeding. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      von Willebrand disease (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/55/6002?source=see_link\">",
"       \"Patient information: von Willebrand disease (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Having a low platelet count",
"     </li>",
"     <li>",
"      Taking a blood thinner like",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?33/2/33830?source=see_link\">",
"       warfarin",
"      </a>",
"      (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/15/21747?source=see_link\">",
"       \"Patient information: Warfarin (Coumadin) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MENORRHAGIA SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with menorrhagia typically have one or more of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Soak through a pad or tampon every one or three hours on the heaviest days of the period Have bleeding for more than seven days",
"     </li>",
"     <li>",
"      Need to use both pads and tampons at the same time due to heavy bleeding",
"     </li>",
"     <li>",
"      Need to change pads or tampons during the night",
"     </li>",
"     <li>",
"      Pass blood clots larger than 1 inch",
"     </li>",
"     <li>",
"      Iron deficiency anemia (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/49/30484?source=see_link\">",
"       \"Patient information: Anemia caused by low iron (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     When to seek help",
"    </span>",
"    &nbsp;&mdash;&nbsp;If you soak through two pads or tampons in one hour for two hours in a row, call your doctor or nurse or go to the emergency department. Bleeding this heavily can be serious or even life threatening.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MENORRHAGIA DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;If you have heavy menstrual bleeding, your doctor or nurse will want to perform a physical exam, including a pelvic exam. The doctor or nurse might recommend other tests, based on what he or she finds during the exam. This can include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood tests to look for a bleeding disorder, anemia, or thyroid disease",
"     </li>",
"     <li>",
"      A pelvic ultrasound uses sound waves to create a picture of the uterus and ovaries. An ultrasound can detect endometrial polyps and fibroids.",
"     </li>",
"     <li>",
"      A biopsy of the tissue inside of the uterus, called an endometrial biopsy. This can be done in the office.",
"     </li>",
"     <li>",
"      A hysteroscopy, which uses a small telescope to look inside the uterus",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MEDICAL TREATMENT FOR MENORRHAGIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best treatment of heavy menstrual bleeding depends on:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The cause of your bleeding",
"     </li>",
"     <li>",
"      Your preferences",
"     </li>",
"     <li>",
"      The need to prevent pregnancy",
"     </li>",
"     <li>",
"      Your desire to have children in the future",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Your doctor or nurse will probably recommend treatment with one or more medicines first. If these treatments do not reduce bleeding enough, a surgical treatment might be an option (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Surgery for menorrhagia'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hormonal birth control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hormonal methods of birth control include the pill, skin patch, vaginal ring, shot, hormonal IUD, and implant. These treatments reduce bleeding during your menstrual period. Hormonal birth control can also reduce cramps and pain during your period. It might take three months for bleeding to improve after you start taking hormonal birth control.",
"   </p>",
"   <p>",
"    Most forms of hormonal birth control, including the pill, skin patch, and vaginal ring, are designed to be used for three weeks in a row, followed by one week off. During the fourth week, you will have menstrual bleeding.",
"   </p>",
"   <p>",
"    More information about hormonal birth control is available separately. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link\">",
"     \"Patient information: Hormonal methods of birth control (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some doctors and nurses advise women with heavy menstrual periods to take hormonal birth control continuously, without a break week. This will allow you to skip your period. This strategy is called continuous dosing.",
"   </p>",
"   <p>",
"    Several brands of birth control pills are packaged with 3 or 12 months of pills to make it easier to take the pill continuously (",
"    <a class=\"graphic graphic_table graphicRef60354 \" href=\"UTD.htm?21/37/22107\">",
"     table 1",
"    </a>",
"    ). You can also take other types of hormonal birth control continuously. This is explained in detail separately. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link&amp;anchor=H15#H15\">",
"     \"Patient information: Hormonal methods of birth control (Beyond the Basics)\", section on 'Continuous dosing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Hormonal intrauterine device",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an intrauterine device (IUD) that slowly releases a hormone, progestin, into the uterus. There is no estrogen in the IUD. This device is called Mirena in the United States and elsewhere. The IUD prevents pregnancy and reduces menstrual bleeding for up to five years (",
"    <a class=\"graphic graphic_picture graphicRef74378 \" href=\"UTD.htm?19/5/19550\">",
"     picture 1",
"    </a>",
"    ). A doctor or nurse places the IUD inside the uterus. This treatment is best for women who do not want to become pregnant in the next six months. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?4/16/4355?source=see_link&amp;anchor=H3#H3\">",
"     \"Patient information: Long-term methods of birth control (Beyond the Basics)\", section on 'Intrauterine device (iud)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Implant",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an implant that slowly releases a progestin into your bloodstream. It prevents pregnancy and reduces menstrual bleeding for up to three years. A doctor or nurse places the implant (which is about the size of a match stick) under the skin in the upper inner arm (",
"    <a class=\"graphic graphic_picture graphicRef82387 \" href=\"UTD.htm?18/25/18847\">",
"     picture 2",
"    </a>",
"    ). It is called Implanon&reg; in the US and elsewhere. This treatment is best for women who do not want to become pregnant in the next six months. This is explained in detail separately. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link&amp;anchor=H23#H23\">",
"     \"Patient information: Hormonal methods of birth control (Beyond the Basics)\", section on 'Birth control implant'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Shot",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?35/25/36245?source=see_link\">",
"     Medroxyprogesterone acetate",
"    </a>",
"    (Depo-Provera&reg;) is a long-acting form of a progesterone-like hormone, called a progestin. It is a shot given once every three months. This treatment prevents pregnancy and can reduce heavy menstrual bleeding. The shot is best for women who do not want to become pregnant in the next six months.",
"   </p>",
"   <p>",
"    The most common side effect of",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?35/25/36245?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    is bleeding and spotting, particularly during the first few months. Many women completely stop having menstrual periods after using this treatment for one year. More detailed information about medroxyprogesterone acetate is available separately. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link&amp;anchor=H19#H19\">",
"     \"Patient information: Hormonal methods of birth control (Beyond the Basics)\", section on 'Injectable birth control'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Antifibrinolytic medicines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antifibrinolytic medicines can help to slow menstrual bleeding quickly. These medicines work by helping the blood clotting system. . Examples include",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?9/51/10037?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    (Lysteda&reg;) and",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?30/17/30996?source=see_link\">",
"     aminocaproic acid",
"    </a>",
"    (Amicar&reg;).",
"   </p>",
"   <p>",
"    The advantages of antifibrinolytic medicines over other medical treatments are that:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The medicine slows bleeding quickly (within two to three hours)",
"     </li>",
"     <li>",
"      You need to take the medicine only a few days each month",
"     </li>",
"     <li>",
"      The medicines do not affect your chances of becoming pregnant",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Side effects can include headache and muscle cramps or pain. You should not take antifibrinolytic medicines with hormonal birth control unless your doctor or nurse approves; there may be an increased risk of blood clots, stroke, and heart attack when taken together.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Nonsteroidal antiinflammatory drugs (NSAIDs)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsteroidal antiinflammatory drugs, such as",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"     ibuprofen",
"    </a>",
"    (sold as Motrin&reg; and Advil&reg;) and",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?19/5/19541?source=see_link\">",
"     mefenamic acid",
"    </a>",
"    (Ponstel&reg;), can help reduce menstrual bleeding and menstrual cramps. You can buy some NSAIDs (including ibuprofen) without a prescription.",
"   </p>",
"   <p>",
"    NSAIDs are not expensive, have few side effects, and reduce pain and bleeding, and you need to take them only during your menstrual period. You can take NSAIDs in combination with any of the medical treatments discussed here. However, NSAIDs do not reduce bleeding as well other medical treatments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Progestin pills",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progestin can also be taken as a pill. Progestin pills are sometimes recommended for women who do not ovulate regularly. The usual dose is one pill per day for 7 to 10 days every one to three months. You will have menstrual bleeding within a week or two of the last dose.",
"   </p>",
"   <p>",
"    This treatment helps to prevent the lining of the uterus from becoming thickened, which can cause excessive bleeding. Progestin pills do not prevent pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Gonadotropin-releasing hormone (GnRH) agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;GnRH agonists are a type of medicine that can be used to temporarily reduce menstrual bleeding. This treatment might be recommended for women who are waiting to have a surgical treatment.",
"   </p>",
"   <p>",
"    These medicines work by \"turning off\" the ovaries, causing a temporary menopause. The medicines can be taken for up to six months. GnRH agonists are not usually recommended for longer than six months in a row due to the risk of weakened bones when used for long periods of time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SURGERY FOR MENORRHAGIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women who have growths in the uterus, such as polyps or fibroids, having a treatment to remove the growth can reduce or end heavy bleeding.",
"   </p>",
"   <p>",
"    Fibroids can be treated by removing them (called myomectomy) or cutting off their blood supply (called uterine artery embolization). These procedures are discussed in depth in a separate article. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?20/20/20804?source=see_link\">",
"     \"Patient information: Uterine fibroids (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other surgical treatments for menorrhagia include:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Endometrial ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometrial ablation is a treatment that destroys or removes most of the lining of the uterus. This can reduce heavy menstrual bleeding or cause you to stop having menstrual bleeding. It is not a good option for women who might want to become pregnant in the future.",
"   </p>",
"   <p>",
"    The treatment can be done in the office or as a day surgery. After the treatment, most women have some cramping, vaginal discharge, and nausea. You may have a pinkish vaginal discharge for two to three days afterward; this gradually becomes clear and watery and can last for 2 to 10 days. Most women can go back to work or school the following day. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?27/27/28083?source=see_link\">",
"     \"Patient information: Care after gynecologic surgery (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Hysterectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hysterectomy is a surgery that removes the uterus. This is a permanent treatment that cures heavy menstrual bleeding. However, the surgery can have complications and may require up to six weeks for full recovery. Pregnancy is not possible after hysterectomy. More detailed information about hysterectomy is available separately. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?6/16/6405?source=see_link\">",
"     \"Patient information: Abdominal hysterectomy (Beyond the Basics)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?33/48/34564?source=see_link\">",
"     \"Patient information: Vaginal hysterectomy (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     WHICH TREATMENT IS RIGHT FOR ME?",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many treatments for heavy menstrual bleeding, and it can be hard to decide which one is right.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Step one",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, you should start with a medical treatment (using a medicine).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If you would like to become pregnant in the next several months, a nonsteroidal antiinflammatory or antifibrinolytic medicine might be a good option (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Nonsteroidal antiinflammatory drugs (NSAIDs)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Antifibrinolytic medicines'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      If you would like to have children eventually, but not soon, a hormonal birth control method, shot, hormonal IUD, or implant might be a good option (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Hormonal birth control'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      If you have no plans to become pregnant in the future, you can use any of the medical treatments described above. Hormonal birth control (including the IUD) and antifibrinolytic medicines are probably the most effective medical treatments.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Step two",
"    </span>",
"    &nbsp;&mdash;&nbsp;If you have tried one or more medical treatments and you still have heavy menstrual bleeding, talk to your doctor or nurse. A surgical treatment might be a good option in this case (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Surgery for menorrhagia'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     WHERE TO GET MORE INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"   </p>",
"   <p>",
"    This article will be updated as needed on our web site (",
"    <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"     www.uptodate.com/patients",
"    </a>",
"    ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1804618067\">",
"    <span class=\"h2\">",
"     Patient level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5515528\">",
"    <span class=\"h3\">",
"     The Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?14/25/14738?source=see_link\">",
"     Patient information: Heavy periods (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?29/17/29970?source=see_link\">",
"     Patient information: Immune thrombocytopenia (ITP) (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?0/8/143?source=see_link\">",
"     Patient information: Endometrial ablation (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?25/13/25810?source=see_link\">",
"     Patient information: Uterine adenomyosis (The Basics)",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5515536\">",
"    <span class=\"h3\">",
"     Beyond the Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?29/12/29891?source=see_link\">",
"     Patient information: Absent or irregular periods (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?20/20/20804?source=see_link\">",
"     Patient information: Uterine fibroids (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?5/55/6002?source=see_link\">",
"     Patient information: von Willebrand disease (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?21/15/21747?source=see_link\">",
"     Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?29/49/30484?source=see_link\">",
"     Patient information: Anemia caused by low iron (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link\">",
"     Patient information: Hormonal methods of birth control (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?4/16/4355?source=see_link\">",
"     Patient information: Long-term methods of birth control (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?27/27/28083?source=see_link\">",
"     Patient information: Care after gynecologic surgery (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?6/16/6405?source=see_link\">",
"     Patient information: Abdominal hysterectomy (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?33/48/34564?source=see_link\">",
"     Patient information: Vaginal hysterectomy (Beyond the Basics)",
"    </a>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Professional level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31866?source=see_link\">",
"     An overview of endometrial ablation",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/41/20122?source=see_link\">",
"     Chronic menorrhagia or anovulatory uterine bleeding",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=see_link\">",
"     Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3832?source=see_link\">",
"     Hormonal contraception for suppression of menstruation",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/25/20887?source=see_link\">",
"     Initial approach to the premenopausal woman with abnormal uterine bleeding",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/18/35113?source=see_link\">",
"     Overview of causes of genital tract bleeding in women",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18666?source=see_link\">",
"     Overview of treatment of uterine leiomyomas (fibroids)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/24/23944?source=see_link\">",
"     Terminology and evaluation of abnormal uterine bleeding in premenopausal women",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2711?source=see_link\">",
"     Postmenopausal uterine bleeding",
"    </a>",
"    <br/>",
"    <br/>",
"    The following organizations also provide reliable health information.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      National Library of Medicine",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;",
"    <span class=\"nowrap\">",
"     (file://www.nlm.nih.gov/medlineplus/)",
"    </span>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8405 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-217.117.136.88-094BD8D684-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_35_23094=[""].join("\n");
var outline_f22_35_23094=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MENORRHAGIA CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Anovulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Growths in the uterus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Bleeding tendency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MENORRHAGIA SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      When to seek help",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MENORRHAGIA DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MEDICAL TREATMENT FOR MENORRHAGIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hormonal birth control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Hormonal intrauterine device",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Implant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Shot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Antifibrinolytic medicines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Nonsteroidal antiinflammatory drugs (NSAIDs)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Progestin pills",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Gonadotropin-releasing hormone (GnRH) agonists",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SURGERY FOR MENORRHAGIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Endometrial ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      WHICH TREATMENT IS RIGHT FOR ME?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Step one",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Step two",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      WHERE TO GET MORE INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1804618067\">",
"      Patient level information",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5515528\">",
"      - The Basics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5515536\">",
"      - Beyond the Basics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Professional level information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/8405\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PI/8405|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/5/19550\" title=\"picture 1\">",
"      Mirena IUD PI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/25/18847\" title=\"picture 2\">",
"      Etonogestrel implant PI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PI/8405|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/37/22107\" title=\"table 1\">",
"      Continuous birth control PI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31866?source=related_link\">",
"      An overview of endometrial ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/41/20122?source=related_link\">",
"      Chronic menorrhagia or anovulatory uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=related_link\">",
"      Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3832?source=related_link\">",
"      Hormonal contraception for suppression of menstruation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/25/20887?source=related_link\">",
"      Initial approach to the premenopausal woman with abnormal uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/18/35113?source=related_link\">",
"      Overview of causes of genital tract bleeding in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18666?source=related_link\">",
"      Overview of treatment of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/16/6405?source=related_link\">",
"      Patient information: Abdominal hysterectomy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/12/29891?source=related_link\">",
"      Patient information: Absent or irregular periods (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/49/30484?source=related_link\">",
"      Patient information: Anemia caused by low iron (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/27/28083?source=related_link\">",
"      Patient information: Care after gynecologic surgery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/8/143?source=related_link\">",
"      Patient information: Endometrial ablation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/25/14738?source=related_link\">",
"      Patient information: Heavy periods (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=related_link\">",
"      Patient information: Hormonal methods of birth control (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/17/29970?source=related_link\">",
"      Patient information: Immune thrombocytopenia (ITP) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/16/4355?source=related_link\">",
"      Patient information: Long-term methods of birth control (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/13/25810?source=related_link\">",
"      Patient information: Uterine adenomyosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/20/20804?source=related_link\">",
"      Patient information: Uterine fibroids (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/48/34564?source=related_link\">",
"      Patient information: Vaginal hysterectomy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/15/21747?source=related_link\">",
"      Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/55/6002?source=related_link\">",
"      Patient information: von Willebrand disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2711?source=related_link\">",
"      Postmenopausal uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/24/23944?source=related_link\">",
"      Terminology and evaluation of abnormal uterine bleeding in premenopausal women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_35_23095="Lomitapide: Drug information";
var content_f22_35_23095=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lomitapide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?16/6/16485?source=see_link\">",
"    see \"Lomitapide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F15845978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F16150139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Juxtapid&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F15848060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antilipemic Agent, Microsomal Triglyceride Transfer Protein (MTP) Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F15883473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Homozygous familial hypercholesterolemia (HoFH):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Transaminases should be measured prior to initiation and any dose increase. Maintenance dose should be individualized, taking into account patient characteristics such as goal of therapy and response to treatment. To reduce development of fat-soluble nutrient deficiency, administer daily supplements containing vitamin E 400 units, linoleic acid &ge;200 mg, alpha-linolenic acid (ALA) 210 mg, eicosapentaenoic acid (EPA) 110 mg, and docosahexaenoic acid (DHA) 80 mg. Initiate a low-fat diet supplying &lt;20% of energy from fat.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Initial: 5 mg once daily; after 2 weeks of therapy, may increase dose to 10 mg once daily, as tolerated;",
"     <i>",
"      then at 4-week intervals,",
"     </i>",
"     the dose may be increased to 20 mg once daily,",
"     <i>",
"      then",
"     </i>",
"     to 40 mg once daily,",
"     <i>",
"      and finally",
"     </i>",
"     to a maximum dose of 60 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Dosage adjustment for lomitapide with",
"     </i>",
"     <b>",
"      <i>",
"       weak",
"      </i>",
"     </b>",
"     <i>",
"      CYP3A inhibitors (eg, amiodarone, amlodipine, atorvastatin, cyclosporine, fluoxetine, oral contraceptives):",
"     </i>",
"     Maximum dose: 30 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F15887642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15883063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Mild-to-severe impairment (not receiving dialysis): No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied); however, it is possible that patients with renal impairment not receiving dialysis may experience increases in lomitapide exposure exceeding 50%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     End stage renal disease (ESRD; receiving dialysis): Maximum dose: 40 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15883064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Mild impairment (Child-Pugh class A): Maximum dose: 40 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Moderate-to-severe impairment (Child-Pugh class B or C), active liver disease (including unexplained persistent transaminase elevations): Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F15883062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;display:inline\">",
"     <b>",
"      Hepatotoxicity:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     If patient experiences clinical symptoms of liver injury (eg, nausea, vomiting, abdominal pain, fever, jaundice, lethargy, flu-like symptoms) with transaminase elevation, increases in bilirubin &ge;2 times ULN, or active liver disease, discontinue use and investigate for probable cause.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      AST or ALT &ge; 3 to &lt;5 times ULN:",
"     </i>",
"     Confirm measurement (within 1 week); once confirmed, reduce dose and obtain additional liver function tests (LFTs) (eg, alkaline phosphatase, total bilirubin, and INR); repeat tests weekly and withhold subsequent doses if signs of abnormal liver function (eg, increased bilirubin or INR), if transaminases rise to &gt;5 times ULN, or if they do not fall to &lt;3 times ULN within ~4 weeks; investigate for probable cause. If resuming after transaminase resolution to &lt;3 times ULN, consider reducing dose and monitor LFTs more frequently.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      AST or ALT &ge; 5 times ULN:",
"     </i>",
"     Withhold doses, obtain additional LFTs (eg, alkaline phosphatase, total bilirubin, and INR); investigate for probable cause. If resuming after transaminase resolution to &lt;3 times ULN, reduce dose and monitor LFTs more frequently.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F16150140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Juxtapid&trade;: 5 mg, 10 mg, 20 mg",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F15882903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As a requirement of the REMS program, access to this medication is restricted. Prescribers must enroll in the Juxtapid&trade; REMS program and complete the Prescriber Training Module and complete, sign, and submit the Prescriber Enrollment Form to the Juxtapid&trade; REMS program. Pharmacies must educate all pharmacy staff involved in the dispensing of Juxtapid&trade; on the REMS program requirements, put processes in place to verify (prior to dispensing Juxtapid&trade;) that the prescriber is certified and the Prescription Authorization Form is received with each new prescription. Pharmacies must also agree to be audited to ensure that all processes and procedures in place are being followed in accordance with the program and be able to provide prescription data to the REMS program.",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F15878136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM333530.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM333530.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F15883065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with a glass of water and without food; administer at least 2 hours after the evening meal since administration with food may increase risk of gastrointestinal adverse effects. Swallow capsules whole (do not open, crush, dissolve, or chew).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F15846000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct to dietary therapy and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol, apolipoprotein B, and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F15882958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Chest pain (24%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fatigue (17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (79%; severe: 14%), nausea (65%), dyspepsia (38%), vomiting (34%; severe: 10%), abdominal pain (34%; severe: 7%), weight loss (24%), abdominal discomfort (21%; severe: 7%), abdominal distension (21%; severe: 7%), constipation (21%), flatulence (21%), gastroenteritis (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Hepatic steatosis (increase in hepatic fat &gt;5%: 78%; &gt;20% fat increase: 13%), ALT increased (17%; severe: 10%), ALT and/or AST &ge;3 times upper limit of normal (34%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Back pain (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Nasopharyngitis (17%), pharyngolaryngeal pain (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Influenza (21%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Angina pectoris (10%), palpitation (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (10%), fever (10%), headache (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Defecation urgency (10%), gastroesophageal reflux disease (10%), rectal tenesmus (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Hepatotoxicity (severe: 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Nasal congestion (10%)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F15882908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pregnancy; concomitant use with moderate or strong CYP3A4 inhibitors; moderate or severe (Child-Pugh class B or C) hepatic impairment; active liver disease including unexplained persistent elevations of serum transaminases",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F15882909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Gastrointestinal events:  Significant gastrointestinal events (eg, diarrhea, nausea, dyspepsia, vomiting) occurred commonly during treatment with lomitapide. Absorption of other oral medications may be affected in patients with diarrhea or vomiting. Adhering to a low-fat diet (&lt;20% of energy from fat) and gradual titration of dosage will reduce the risk of gastrointestinal adverse events.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: May cause transaminase elevations; elevations in ALT or AST &ge;3 times upper limit of normal occurred during clinical trials (no clinically meaningful concomitant bilirubin, INR, or alkaline phosphatase elevation was observed). Lomitapide also increases hepatic fat, with or without concomitant transaminase elevations. Hepatic steatosis associated with lomitapide (reversible upon discontinuation) may be a risk factor for progressive liver disease including steatohepatitis and cirrhosis. Monitor hepatic function (ALT, AST, alkaline phosphatase and total bilirubin) prior to treatment; monitor ALT and AST regularly as recommended during treatment; dosage adjustment or discontinuation may be necessary; transaminases typically reduce within 1-4 weeks after discontinuation.",
"     </b>",
"     Alcohol ingestion may increase the risk of hepatic steatosis; alcohol consumption should be limited to &le;1 drink/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Use with caution in patients with mild (Child-Pugh class A) hepatic impairment due to increased drug exposure; a reduced maximum dose of 40 mg daily is recommended. Use is contraindicated in patients with moderate to severe (Child-Pugh class B or C) impairment or active liver disease including unexplained persistent elevations of serum transaminases.  If abnormal liver function tests have been explained or resolved, consideration may be given to initiation of lomitapide. Monitor liver function as recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use with caution in patients with mild-to-severe renal impairment including end stage renal disease (ESRD) not receiving dialysis (has not been evaluated); exposure may significantly increase. Use with caution in patients with ESRD receiving dialysis; a lower maximum dose of 40 mg daily is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; CYP3A4 inhibitors: Use with caution in patients receiving weak CYP3A4 inhibitors; a lower maximum dose of 30 mg daily is recommended. Concomitant use with moderate or strong CYP3A4 inhibitors is contraindicated; if treatment with moderate or strong CYP3A4 inhibitors is unavoidable, discontinue use of lomitapide. Avoid grapefruit juice during lomitapide treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Fat-soluble vitamins: Lomitapide may reduce the absorption of fat-soluble nutrients (eg, vitamin E, linoleic acid, alpha-linolenic acid, eicosapentaenoic acid, and docosahexaenoic acid); supplementation is recommended. Patients with chronic bowel or pancreatic diseases predisposed to malabsorption are at increased risk for deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatotoxic medications: Use caution when administered concomitantly with other hepatotoxic medications (eg, acetaminophen [&gt;4 g/day for &ge;3 days/week], amiodarone, isotretinoin, methotrexate, tetracyclines, and tamoxifen); may require more frequent monitoring of liver function tests.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; HMG-CoA reductase inhibitors: Lomitapide approximately doubles exposure to simvastatin; when used concurrently, the dose of simvastatin should be reduced by 50% and limited to a maximum dose of 20 mg daily (or 40 mg daily for those who previously tolerated simvastatin 80 mg daily for &ge;1 year without evidence of muscle toxicity). Interaction with other HMG-CoA reductase inhibitors (eg, lovastatin) has not been studied; however dosage reduction should be considered with those that are metabolized similar to simvastatin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Warfarin: Use caution when administered concomitantly with warfarin; plasma warfarin concentrations may increase leading to supratherapeutic anticoagulation; decreases in lomitapide doses may lead to subtherapeutic anticoagulation. Monitor INR more closely especially after lomitapide dose changes (upward or downward) and adjust warfarin dose as clinically indicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Lactose: Contains lactose; avoid use in patients with hereditary galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption; may result in diarrhea and malabsorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; REMS program:",
"     <b>",
"      [U.S. Boxed Warning]: Due to the risk for hepatotoxicity, access is restricted through a REMS program (Juxtapid&trade;  REMS program).",
"     </b>",
"     Only certified healthcare providers and pharmacies may prescribe and dispense lomitapide. Further information on the REMS program is available at www.JUXTAPIDREMSprogram.com or at 1-855-898-2743.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F15977043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2B6 (minor), CYP2C19 (minor), CYP2C8 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (moderate), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F15977041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the hepatotoxic effect of Lomitapide. Management: Advise patients to limit alcohol consumption to 1 drink per day while receiving lomitapide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil adult dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor.  Patients receiving such a combination should also be monitored more closely for evidence of adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Lomitapide. Management: Administer lomitapide at least 4 hours before or after administration of a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Weak): May increase the serum concentration of Lomitapide. Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.  Management: When used concomitantly with moderate inhibitors of CYP3A4, eplerenone dosing recommendations may vary depending on international labeling. Consult appropriate labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivabradine.  Management: In patients with a resting heart rate over 60 beats per minute receiving a moderate CYP3A4 inhibitor, ivabradine initiation at an adult dose of 2.5 mg twice daily may be considered.  Monitor heart rate closely under these circumstances.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg daily in patients also receiving moderate CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: Lomitapide may increase the serum concentration of Lovastatin.  Management: Consider reducing lovastatin doses during concomitant treatment with lomitapide, and monitor for signs and symptoms of muscle toxicity.  Specific dosing recommendations are not presently available.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: U.S. labeling: start at 20 mg/day and limit to max of 80 mg/day with moderate CYP3A4 inhibitor.  Canadian labeling: limit to max of 40 mg/day with moderate CYP3A4 inhibitor; avoid concomitant use of grapefruit products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.  Management: Limit the ranolazine adult dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: Lomitapide may increase the serum concentration of Simvastatin.  Management: Reduce the recommended simvastatin dose by 50%. Generally, limit the maximum adult simvastatin dose to 20 mg/day. A 40 mg/day dose can be considered in patients who previously received 80 mg/day for at least a year without evidence of muscle toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Lomitapide may increase the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F15882995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: May increase the risk for hepatic steatosis. Management: Limit alcohol consumption to 1 drink per day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Grapefruit juice may increase lomitapide plasma concentration. Management: Avoid grapefruit juice.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     High-fat diet: Diets containing &ge;20% of total calories from fat may increase the risk of gastrointestinal adverse reactions (eg, abdominal pain/discomfort, constipation, diarrhea, flatulence, and nausea/vomiting).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Absorption of fat-soluble nutrients may be reduced. Management: Take recommended daily supplements of vitamin E, alpha-linolenic acid (ALA), linoleic acid, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F15882904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F15882905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed in animal reproduction studies using doses lower than equivalent human doses. Use is contraindicated in pregnant women. Discontinue immediately if pregnancy occurs during treatment. Women of reproductive potential should have a negative pregnancy test prior to therapy and effective contraception must be used during treatment. Dose adjustment may be required for women using oral contraceptives.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F15882906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F15882907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if lomitapide is excreted into breast milk. Due to the potential for serious adverse reactions in the nursing infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Juxtapid Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (28): $21636.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (28): $21636.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (28): $27156.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F15883072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Baseline: ALT, AST, alkaline phosphatase, total bilirubin; pregnancy test in females of reproductive potential; measure transaminases prior to any increase in dose or monthly (whichever occurs first) during the first year, and then at least every 3 months and prior to dosage increases (also see Dosage Adjustment for Toxicity)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F15882998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lomitapide directly binds to and inhibits microsomal triglyceride transfer protein (MTP) which is located in the lumen of the endoplasmic reticulum. MTP inhibition prevents the assembly of apo-B containing lipoproteins in enterocytes and hepatocytes resulting in reduced production of chylomicrons and VLDL and subsequently reduces plasma LDL-C concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F15883006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Mean V",
"     <sub>",
"      d",
"     </sub>",
"     : 985-1292 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 99.8% to plasma proteins",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Primarily hepatic (extensive) through CYP3A4 to M1 and M3 (major [inactive",
"     <i>",
"      in vitro",
"     </i>",
"     ] metabolites); CYP1A2, CYP2B6, CYP2C8, and CYP2C19 are also involved in metabolism to a minor degree.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: ~7%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 39.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: ~6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (53% to 60%; major component: M1 metabolite); feces (33% to 35%; major component: parent drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Cuchel M, Bloedon LT, Szapary PO, et al, &ldquo;Inhibition of Microsomal Triglyceride Transfer Protein in Familial Hypercholesterolemia,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 356(2):148-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/35/23095/abstract-text/17215532/pubmed\" id=\"17215532\" target=\"_blank\">",
"        17215532",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cuchel M, Meagher EA, du Toit Theron H, et al, &ldquo;Efficacy and Safety of a Microsomal Triglyceride Transfer Protein Inhibitor in Patients With Homozygous Familial Hypercholesterolemia: A Single-Arm, Open-Label, Phase 3 Study,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2013, 381(9860):40-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/35/23095/abstract-text/23122768/pubmed\" id=\"23122768\" target=\"_blank\">",
"        23122768",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Samaha FF, McKenney J, Bloedon LT, et al, &ldquo;Inhibition of Microsomal Triglyceride Transfer Protein Alone or With Ezetimibe in Patients With Moderate Hypercholesterolemia,&rdquo;",
"      <i>",
"       Nat Clin Pract Cardiovasc Med",
"      </i>",
"      , 2008, 5(8):497-505.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/35/23095/abstract-text/18506154/pubmed\" id=\"18506154\" target=\"_blank\">",
"        18506154",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87508 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-15E18CE5C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_35_23095=[""].join("\n");
var outline_f22_35_23095=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15845978\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16150139\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15848060\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15883473\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15887642\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15883063\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15883064\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15883062\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16150140\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15882903\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15878136\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15883065\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15846000\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15882958\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15882908\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15882909\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15977043\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15977041\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15882995\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15882904\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15882905\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15882906\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15882907\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570466\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15883072\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15882998\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15883006\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/87508\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/87508|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/6/16485?source=related_link\">",
"      Lomitapide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_35_23096="Ibuprofen and famotidine: Drug information";
var content_f22_35_23096=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ibuprofen and famotidine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?34/60/35781?source=see_link\">",
"    see \"Ibuprofen and famotidine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F12807994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F12993070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Duexis&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F12783084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       2",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Nonsteroidal Anti-inflammatory Drug (NSAID), Oral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F12808097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      NSAID-associated ulcer prophylaxis during treatment for osteoarthritis/rheumatoid arthritis:",
"     </b>",
"     Oral: One tablet (800 mg ibuprofen/26.6 mg famotidine) 3 times daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F12808098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F12808099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute: Use not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15897589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F12808116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duexis&reg;: Ibuprofen 800 mg and famotidine 26.6 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F12807997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F12807996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM253076.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM253076.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F12808112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with or without food. Tablets should be swallowed whole; do not chew, crush, or split.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F12783085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduction of the risk of NSAID-associated gastric ulcers in patients who require an NSAID for the treatment of rheumatoid arthritis or osteoarthritis",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F12808015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Percentages as reported for combination product. Also see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Hypertension (3%), peripheral edema (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (6%), diarrhea (5%), dyspepsia (5%), constipation (4%), abdominal pain/discomfort (2% to 3%), GERD (2%), vomiting (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Urinary tract infection (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Anemia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Back pain (2%), arthralgia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Upper respiratory tract infection (4%), bronchitis (2%), cough (2%), nasopharyngitis (2%), pharyngolaryngeal pain (2%), sinusitis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Influenza (2%)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F12808003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to H",
"     <sub>",
"      2",
"     </sub>",
"     -receptor antagonists; history of asthma, urticaria, or allergic-type reaction to aspirin or other NSAIDs; perioperative pain in the setting of coronary artery bypass graft (CABG) surgery; late stages of pregnancy (&gt;30 weeks)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F12808004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid reactions: Even in patients without prior exposure anaphylactoid reactions may occur; patients with \"aspirin triad\" (bronchial asthma, aspirin intolerance, rhinitis) may be at increased risk. Do not use in patients who experience bronchospasm, asthma, rhinitis, or urticaria with NSAID or aspirin therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular events:",
"     <b>",
"      [U.S. Boxed Warning]: NSAIDs are associated with an increased risk of adverse cardiovascular thrombotic events, including fatal MI and stroke.",
"     </b>",
"     Risk may be increased with duration of use or pre-existing cardiovascular risk factors or disease. Carefully evaluate individual cardiovascular risk profiles prior to prescribing. Use caution with fluid retention. Avoid use in heart failure. Concurrent administration of ibuprofen, and potentially other nonselective NSAIDs, may interfere with aspirin&rsquo;s cardioprotective effect. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of cardiovascular events; alternate therapies should be considered for patients at high risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May cause drowsiness, dizziness, blurred vision, and other neurologic effects which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Confusion, delirium, seizures, and coma have been linked to famotidine use. Increased age (&gt;50 years) and renal or hepatic impairment are thought to be associated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal events:",
"     <b>",
"      [U.S. Boxed Warning]: NSAIDs may increase risk of gastrointestinal irritation, inflammation, ulceration, bleeding, and perforation.",
"     </b>",
"     These events can be fatal and may occur at any time during therapy and without warning. Use caution with a history of GI disease (bleeding or ulcers), concurrent therapy with aspirin, anticoagulants and/or corticosteroids, smoking, use of ethanol, the elderly or debilitated patients. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of GI adverse events; alternate therapies should be considered for patients at high risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic effects: Platelet adhesion and aggregation may be decreased; may prolong bleeding time; patients with coagulation disorders or who are receiving anticoagulants should be monitored closely. Anemia may occur; patients on long-term NSAID therapy should be monitored for anemia. Rarely, NSAID use has been associated with potentially severe blood dyscrasias (eg, agranulocytosis, thrombocytopenia, aplastic anemia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: NSAID use may increase the risk of hyperkalemia, particularly in the elderly, diabetics, renal disease, and with concomitant use of other agents capable of inducing hyperkalemia (eg, ACE-inhibitors). Monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ophthalmic events: Blurred/diminished vision, scotomata, and changes in color vision have been reported. Discontinue therapy and refer for ophthalmologic evaluation if symptoms occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin reactions: NSAIDs may cause serious skin adverse events including exfoliative dermatitis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN); discontinue use at first sign of skin rash or hypersensitivity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aseptic meningitis: May increase the risk of aseptic meningitis, especially in patients with systemic lupus erythematosus (SLE) and mixed connective tissue disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Do not administer to patients with aspirin-sensitive asthma; severe bronchospasm may occur. Use caution in patients with other forms of asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coronary artery bypass graft surgery:",
"     <b>",
"      [U.S. Boxed Warning]: Use is contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.",
"     </b>",
"     Risk of MI and stroke may be increased with use following CABG surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastric malignancy: Relief of symptoms does not preclude the presence of a gastric malignancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with decreased hepatic function. Closely monitor patients with any abnormal LFT. Severe hepatic reactions (eg, fulminant hepatitis, liver failure) have occurred with NSAID use, rarely; discontinue if signs or symptoms of liver disease develop, or if systemic manifestations occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: Use with caution; NSAIDs may cause new-onset hypertension or worsening of existing hypertension. Response to ACE inhibitors, thiazides, or loop diuretics may be impaired with concurrent use of NSAIDs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: NSAID use may compromise existing renal function; dose-dependent decreases in prostaglandin synthesis may result from NSAID use, reducing renal blood flow which may cause renal decompensation. Patients with impaired renal function, dehydration, heart failure, liver dysfunction, those taking diuretics, and ACE inhibitors, and the elderly are at greater risk of renal toxicity. Rehydrate patient before starting therapy; monitor renal function closely. Long-term NSAID use may result in renal papillary necrosis. Famotidine adverse effects may be increased in patients with moderate-to-severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute); use is not recommended since product contains a fixed amount of famotidine and dose cannot be adjusted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: The elderly are at increased risk for adverse effects (especially serious gastrointestinal events, CNS effects, renal toxicity) from NSAIDs even at low doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical/dental procedures: Withhold for at least 4-6 half-lives prior to surgical or dental procedures.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F12808039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F12817733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: H2-Antagonists may decrease the serum concentration of Atazanavir.  Management: Specific dose limitations and administration guidelines exist; consult full interaction monograph or atazanavir prescribing information.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: H2-Antagonists may decrease the serum concentration of Bosutinib.  Management: Administer histamine H2 receptor antagonists more than 2 hours before or after bosutinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefditoren: H2-Antagonists may decrease the serum concentration of Cefditoren.  Management: Concomitant use of cefditoren with H2-antagonists and antacids is not recommended. Consider alternative methods to control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of H2-antagonists can not be avoided.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefpodoxime: H2-Antagonists may decrease the absorption of Cefpodoxime. Separate oral doses by at least 2 hours.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefuroxime: H2-Antagonists may decrease the absorption of Cefuroxime. Separate oral doses by at least 2 hours.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: H2-Antagonists may decrease the absorption of Dasatinib.  Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of H2-antagonists if some acid-reducing therapy is needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: H2-Antagonists may decrease the serum concentration of Delavirdine.  Management: Chronic therapy with H2-antagonists should be avoided in patients who are being treated with delavirdine.  The clinical significance of short-term H2-antagonist therapy with delavirdine is uncertain, but such therapy should be undertaken with caution.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: H2-Antagonists may increase the absorption of Dexmethylphenidate. Specifically, H2-antagonists may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: H2-Antagonists may decrease the serum concentration of Erlotinib.  Management: Avoid H2-antagonists in patients receiving erlotinib when possible.  If concomitant treatment cannot be avoided, erlotinib should be dosed once daily, 10 hours after and at least 2 hours before H2-antagonist dosing.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: H2-Antagonists may decrease the serum concentration of Fosamprenavir. Cimetidine may also inhibit the metabolism of the active metabolite amprenavir, making its effects on fosamprenavir/amprenavir concentrations difficult to predict.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: H2-Antagonists may decrease the serum concentration of Gefitinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Ibuprofen may decrease the serum concentration of Imatinib. Specifically, ibuprofen may decrease intracellular concentrations of imatinib, leading to decreased clinical response.  Management: Consider using an alternative to ibuprofen in patients who are being treated with imatinib.  Available evidence suggests other NSAIDs do not interact in a similar manner.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: H2-Antagonists may decrease the serum concentration of Indinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: H2-Antagonists may decrease the absorption of Iron Salts.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: H2-Antagonists may decrease the serum concentration of Itraconazole.  Management: When this combination is used, the itraconazole should be administered with a cola beverage (8 ounces). Itraconazole oral suspension may be less sensitive to this interaction.  Monitor patient response to itraconazole closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): H2-Antagonists may decrease the serum concentration of Ketoconazole (Systemic).  Management: Administer oral ketoconazole at least 2 hours prior to use of any H2-receptor antagonist.  Monitor patients closely for signs of inadequate clinical response to ketoconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics.  Management: Monitor for decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concomitant use of these agents in CHF or cirrhosis with ascites. Concomitant use of bumetanide with indomethacin is  not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mesalamine: H2-Antagonists may diminish the therapeutic effect of Mesalamine. Histamine H2-Antagonist-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Consider avoiding concurrent administration of high-dose histamine H2-receptor antagonists with sustained-release mesalamine products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: H2-Antagonists may increase the absorption of Methylphenidate. Specifically, H2-antagonists may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): H2-Antagonists may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, the absorption of iron may be impaired by H2-antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: H2-Antagonists may decrease the serum concentration of Nelfinavir. Concentrations of the active M8 metabolite may also be reduced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: H2-Antagonists may decrease the serum concentration of Nilotinib.  Management: Separate the administration of nilotinib and the H2 receptor antagonist by several hours whenever possible in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of other Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PEMEtrexed: NSAID (Nonselective) may increase the serum concentration of PEMEtrexed.  Management: Patients with mild-to-moderate renal insufficiency (estimated creatinine clearance 45-79 mL/min) should avoid NSAIDs for 2-5 days prior to, the day of, and 2 days after pemetrexed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: H2-Antagonists may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: H2-Antagonists may decrease the serum concentration of Posaconazole.  Management: Avoid concurrent use whenever possible.  Monitor patients closely for decreased antifungal effects if this combination is used.  Consider using a noninteracting antifungal as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: H2-Antagonists may decrease the serum concentration of Rilpivirine.  Management: Administer histamine H2 receptor antagonists at least 12 hours before or 4 hours after rilpivirine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Risedronate: H2-Antagonists may increase the serum concentration of Risedronate. This applies specifically to delayed-release risedronate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Choline Magnesium Trisalicylate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: H2-Antagonists may increase the serum concentration of Saquinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Varenicline: H2-Antagonists may increase the serum concentration of Varenicline.  Management: Monitor for increased varenicline adverse effects with concomitant use of cimetidine or other H2-antagonists, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vismodegib: H2-Antagonists may decrease the serum concentration of Vismodegib.  Management: Carefully consider the need for any medication that increases the pH of the upper GI tract (PPIs, H2RAs, antacids), as these could significantly reduce vismodegib systemic exposure. Vismodegib dose increases are unlikely to compensate for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): NSAID (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Ibuprofen. Specifically, concentrations of the S-(+)-ibuprofen enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F12808040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may enhance gastric mucosal irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Ibuprofen peak serum levels may be decreased if taken with food.  Famotidine bioavailability may be increased if taken with food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid alfalfa, anise, bilberry, bladderwrack, bromelain, cat's claw, celery, chamomile, coleus, cordyceps, dong quai, evening primrose, fenugreek, feverfew, garlic, ginger, ginkgo biloba, ginseng (American, Panax, Siberian), grapeseed, green tea, guggul, horse chestnut seed, horseradish, licorice, prickly ash, red clover, reishi, SAMe (S-adenosylmethionine), sweet clover, turmeric, white willow (all have additional antiplatelet activity).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F12807998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F12807999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted with this combination. Use is contraindicated in late stages of pregnancy (&ge;30 weeks gestation). See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F12808000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F12808002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F12808111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Duexis Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     800-26.6 mg (90): $602.64",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F12808114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC, chemistry profile, occult blood loss, periodic liver function tests; monitor response (pain, range of motion, grip strength, mobility, ADL function), inflammation; observe for weight gain, edema; monitor renal function (urine output, serum BUN and creatinine); observe for bleeding, bruising; evaluate gastrointestinal effects (abdominal pain, bleeding, dyspepsia); mental confusion, disorientation; with long-term therapy, periodic ophthalmic exams",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F12808043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibuprofen: Reversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, which results in in decreased formation of prostaglandin precursors; has antipyretic, analgesic, and anti-inflammatory properties",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Famotidine: Competitive inhibition of histamine at H",
"     <sub>",
"      2",
"     </sub>",
"     receptors of the gastric parietal cells, which inhibits gastric acid secretion",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F12808045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Hochberg MC, Altman RD, April KT, et al, &ldquo;American College of Rheumatology 2012 Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee,&rdquo;",
"      <i>",
"       Arthritis Care Res (Hoboken)",
"      </i>",
"      , 2012, 64(4):465-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/35/23096/abstract-text/22563589/pubmed\" id=\"22563589\" target=\"_blank\">",
"        22563589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lanza FL, Chan FK, and Quigley EM, &ldquo;Guidelines for Prevention of NSAID-Related Ulcer Complications,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2009, 140(3):728-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/35/23096/abstract-text/19240698/pubmed\" id=\"19240698\" target=\"_blank\">",
"        19240698",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16488 Version 24.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-5088ACF45B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_35_23096=[""].join("\n");
var outline_f22_35_23096=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12807994\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12993070\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12783084\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12808097\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12808098\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12808099\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897589\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12808116\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12807997\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12807996\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12808112\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12783085\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12808015\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12808003\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12808004\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12808039\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12817733\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12808040\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12807998\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12807999\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12808000\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12808002\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12808111\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322898\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12808114\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12808043\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12808045\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16488\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16488|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/60/35781?source=related_link\">",
"      Ibuprofen and famotidine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_35_23097="Gianotti-Crosti syndrome (papular acrodermatitis)";
var content_f22_35_23097=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Gianotti-Crosti syndrome (papular acrodermatitis)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/35/23097/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/35/23097/contributors\">",
"     Antonio A T Chuh, MD, FRCP, FRCPCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/35/23097/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/35/23097/contributors\">",
"     Moise L Levy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/35/23097/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/35/23097/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/35/23097/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/35/23097/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gianotti-Crosti syndrome (GCS), also known as papular acrodermatitis, papular acrodermatitis of childhood, and infantile papular acrodermatitis, is a symmetric papular eruption with an acral distribution (cheeks, buttocks, and extensor surfaces of the forearms and legs) (",
"    <a class=\"graphic graphic_picture graphicRef67780 graphicRef56024 \" href=\"UTD.htm?12/51/13111\">",
"     picture 1A-B",
"    </a>",
"    ). It was first described by Gianotti in 1955, and by Crosti and Gianotti in 1957 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], and was initially believed to occur only in infants and children [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. It has since been reported in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the original descriptions, GCS had three cardinal manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonrelapsing erythemato-papular dermatitis localized to the face and limbs, lasting about three weeks",
"     </li>",
"     <li>",
"      Paracortical hyperplasia of lymph nodes",
"     </li>",
"     <li>",
"      Acute hepatitis, usually anicteric, which could last for months and progress to chronic liver disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Gianotti referred to papular or papulovesicular acral eruptions, with or without itching, associated with reactive lymphadenitis, but not hepatitis, as \"papulovesicular acrolocated syndrome\" [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/4\">",
"     4",
"    </a>",
"    ]. However, it is not possible to distinguish between GCS and papulovesicular acrolocated syndrome solely on the basis of cutaneous findings [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With current terminology, neither lymphadenopathy nor hepatitis is mandatory for the diagnosis of GCS. The term \"Gianotti-Crosti disease\" is sometimes reserved for patients with GCS that is documented to be related to hepatitis B virus (HBV) infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence and prevalence of GCS are unknown. Because many children with GCS may be diagnosed with a \"viral rash\" or \"nonspecific viral exanthem,\" GCS is probably underdiagnosed [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    GCS primarily affects children younger than five years of age. During childhood, boys and girls are equally affected [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. However, in adulthood, females may be more prone than males to develop GCS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most reports of GCS describe isolated cases. However, several outbreaks have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/14-18\">",
"     14-18",
"    </a>",
"    ]. Three outbreaks in Japan were associated with HBV and involved 153, 54, and 14 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. The remaining two outbreaks were associated with Epstein-Barr virus (EBV) infection, and each involved five patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. A mini-epidemic with four patients was reported, but the underlying virological cause was not found [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;GCS usually occurs in association with a viral illness. HBV and EBV are the most common causes. In a review of 308 cases, 22 percent were caused by HBV and 78 percent by other viruses [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hepatitis B virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association of GCS with HBV infection is well known [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/9,14-16,20-23\">",
"     9,14-16,20-23",
"    </a>",
"    ]. However, HBV is an uncommon cause of GCS in the United States and in other countries where universal hepatitis B vaccination during infancy is routine [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/10\">",
"     10",
"    </a>",
"    ]. In infants and young children with acute HBV infection, GCS may be the only clinical manifestation. The clinical manifestations, treatment, and prevention of hepatitis B virus are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/41/31386?source=see_link\">",
"     \"Overview of hepatitis B virus infection in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4602?source=see_link\">",
"     \"Epidemiology, transmission, and prevention of hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H15\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Epstein-Barr virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epstein-Barr virus is another common cause of GCS, accounting for approximately one-half to three-quarters of cases in some series [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/12,24-28\">",
"     12,24-28",
"    </a>",
"    ]. The clinical manifestations and treatment of EBV infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=see_link\">",
"     \"Clinical manifestations and treatment of Epstein-Barr virus infection\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H15\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;GCS is less commonly reported in association with other pathogens, including enteroviruses [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/29,30\">",
"     29,30",
"    </a>",
"    ], cytomegalovirus [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/31-33\">",
"     31-33",
"    </a>",
"    ], parvovirus [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/34,35\">",
"     34,35",
"    </a>",
"    ], parainfluenza virus [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/36,37\">",
"     36,37",
"    </a>",
"    ], hepatitis A virus [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/38,39\">",
"     38,39",
"    </a>",
"    ], rotavirus [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/40,41\">",
"     40,41",
"    </a>",
"    ], molluscum contagiosum [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/34,42\">",
"     34,42",
"    </a>",
"    ], respiratory syncytial virus [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/30\">",
"     30",
"    </a>",
"    ], human immunodeficiency virus [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/43\">",
"     43",
"    </a>",
"    ], human herpesvirus 6 (mainly 6B) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/44,45\">",
"     44,45",
"    </a>",
"    ], Mycoplasma pneumoniae [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/46,47\">",
"     46,47",
"    </a>",
"    ], beta-hemolytic streptococci [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/30\">",
"     30",
"    </a>",
"    ], Bartonella henselae [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/48\">",
"     48",
"    </a>",
"    ], and Borrelia burgdorferi [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/49\">",
"     49",
"    </a>",
"    ]. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;GCS has been reported to occur after the administration of various vaccines, including influenza virus vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/50\">",
"     50",
"    </a>",
"    ], measles-mumps-rubella vaccines [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/51\">",
"     51",
"    </a>",
"    ], hepatitis B and measles vaccines [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/52,53\">",
"     52,53",
"    </a>",
"    ], oral polio vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/54\">",
"     54",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/30/44518?source=see_link\">",
"     hepatitis A vaccine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/55\">",
"     55",
"    </a>",
"    ], and Japanese encephalitis vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/56\">",
"     56",
"    </a>",
"    ]. However, many children receive vaccinations before any disease event; such temporal associations may be purely coincidental and cannot be taken as definitive evidence for a causal association.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of GCS, including the mechanism for the acral distribution of lesions, is unknown. Lesional histopathologic changes are nonspecific, and include focal spongiosis (collections of fluid in the epidermis) and parakeratosis with perivascular lymphocytic infiltrates in the upper dermis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations of GCS may represent a final common pathway for infections caused by several viruses. One hypothesis suggests that the clinical manifestations result from a delayed hypersensitivity reaction to viral illness [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The significance of IgE-mediated immunity in the pathogenesis of GCS and other viral exanthems is another area of investigation. A case-control study noted that children with GCS were significantly more likely to have had atopic dermatitis and to have a family history of atopy than control children who were being evaluated for recurrent infections (24 versus 7 percent for atopic dermatitis and 52 versus 31 percent for family history of atopy) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;GCS usually occurs in children younger than five years, but older children, adolescents, and adults also may be affected. Most patients have an upper respiratory or gastrointestinal illness in the week before the onset of the rash [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/10\">",
"     10",
"    </a>",
"    ]; the initial illness may have resolved by the time the child presents with the rash.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Dermatologic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;GCS presents as a sudden symmetric eruption of multiple small papular or papulovesicular lesions. The lesions are monomorphous, flat-topped, pink-brown papules or papulovesicles, 1 to 10 mm in diameter; they may coalesce into plaques (",
"    <a class=\"graphic graphic_picture graphicRef67780 graphicRef56024 \" href=\"UTD.htm?12/51/13111\">",
"     picture 1A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/10,60\">",
"     10,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The face, buttocks, extensor aspects of forearms and legs, and feet are predominantly affected. Truncal lesions are commonly present, although more transient and fewer in number than acrally distributed lesions. The presence of truncal lesions does not exclude a diagnosis of GCS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/61\">",
"     61",
"    </a>",
"    ]. The mucosal surfaces and nails are not involved [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/62,63\">",
"     62,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The appearance of lesions at sites of trauma (ie, the Koebner phenomenon) may be seen during the early phase [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/12,63\">",
"     12,63",
"    </a>",
"    ]. Pruritus usually is of mild to moderate severity; however, the spectrum ranges from absent to severe.",
"   </p>",
"   <p>",
"    Hemorrhagic changes occasionally occur, particularly in areas subject to trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/10,60,63\">",
"     10,60,63",
"    </a>",
"    ]. It has been suggested that patients with petechial lesions are more likely to have HBV [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/64\">",
"     64",
"    </a>",
"    ]. However, the cutaneous findings of GCS are not helpful in determining whether GCS is caused by HBV, EBV, or another etiologic agent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/41/31386?source=see_link\">",
"     \"Overview of hepatitis B virus infection in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Affected patients may have concurrent malaise, low-grade fever, or diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/10\">",
"     10",
"    </a>",
"    ]. Lymphadenopathy is present in 25 to 35 percent of patients, usually in the cervical, axillary, or inguinal regions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/12,65\">",
"     12,65",
"    </a>",
"    ]. The frequency of hepatic involvement is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/10\">",
"     10",
"    </a>",
"    ]. When hepatitis is present, it usually is anicteric (without clinically recognized jaundice) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/5,66\">",
"     5,66",
"    </a>",
"    ]. Splenomegaly may occur, but is uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neither lymphadenopathy nor hepatomegaly is necessary to make a diagnosis of GCS. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no laboratory features characteristic of GCS. Patients with GCS may have modest lymphocytosis or lymphopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/10\">",
"     10",
"    </a>",
"    ]. Liver enzymes may be elevated in patients with EBV, CMV, or hepatitis-associated disease. Skin biopsy may be useful in cases that are clinically confusing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most children with GCS have an excellent prognosis, although the course may be prolonged [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/10\">",
"     10",
"    </a>",
"    ]. Spontaneous remission of the rash without active intervention is the rule. The rash usually lasts from 10 days to 6 months; however, durations ranging from 5 days to 12 months have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/65\">",
"     65",
"    </a>",
"    ]. Pruritus may last for weeks.",
"   </p>",
"   <p>",
"    In the initial two to three weeks, new papules and papulovesicles continue to occur, and the areas of involvement expand. The distribution of eruption is most classic in the middle phase of the disease. Near the end of the course, slow resolution of the lesions occurs. There may be mild postinflammatory hyperpigmentation or hypopigmentation. However, scarring",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pigment changes usually are not permanent. Recurrences are possible, but rare [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lymphadenopathy and hepatomegaly (or hepatosplenomegaly) usually take longer to resolve than the cutaneous lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/21,63\">",
"     21,63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postinflammatory hypopigmentation or hyperpigmentation occurs frequently in children with darker skin types and can persist for months after resolution of the rash, but eventually resolves [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/10,68\">",
"     10,68",
"    </a>",
"    ]. Permanent scarring is infrequent, even for children with facial involvement.",
"   </p>",
"   <p>",
"    Other potential complications are related to the underlying etiology. Complications related to EBV infection, including splenic rupture, or lymphoproliferative disorders, are theoretically possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations and treatment of Epstein-Barr virus infection\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with acute HBV infection may progress to chronic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/14\">",
"     14",
"    </a>",
"    ]. The age at the time of acute infection is the main determinant of the risk of progression: more than 90 percent of infants infected perinatally, and 25 to 50 percent of children infected between one and five years of age, develop chronic HBV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/69\">",
"     69",
"    </a>",
"    ]. The natural history of chronic HBV infection in children is variable, depending upon age, mode of acquisition, and ethnicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/41/31386?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of hepatitis B virus infection in children\", section on 'Natural history'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;GCS is a clinical diagnosis. Laboratory investigations are not helpful in establishing the diagnosis in young children, but may be necessary to determine the etiology or to exclude other conditions in the differential diagnosis, particularly if the eruption or course is atypical for GCS. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Clinical diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The essential clinical features of the diagnosis are [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/65,70\">",
"     65,70",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Monomorphous, flat-topped, pink-brown papules or papulovesicles 1 to 10 mm in diameter (",
"      <a class=\"graphic graphic_picture graphicRef67780 graphicRef56024 \" href=\"UTD.htm?12/51/13111\">",
"       picture 1A-B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Involvement of at least three out of four acral sites (cheeks, buttocks, extensor surfaces of forearms, extensor surfaces of legs)",
"     </li>",
"     <li>",
"      Symmetry of lesions",
"     </li>",
"     <li>",
"      Duration of at least 10 days",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical features that exclude the diagnosis include [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/70\">",
"     70",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extensive truncal lesions",
"     </li>",
"     <li>",
"      Scaly lesions",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Skin biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lesional histopathologic changes are nonspecific and cannot confirm the diagnosis. However, lesional skin biopsy may be necessary to exclude other considerations in the differential diagnosis if the rash is atypical (eg, more prominent truncal than acral distribution or lack of spontaneous resolution in six months). (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Etiologic diagnosis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26396446\">",
"    <span class=\"h3\">",
"     HBV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether HBV serology and liver function tests are indicated for children with a diagnosis of GCS is controversial. On the one hand, HBV is an uncommon cause of GCS in countries where universal hepatitis B vaccination during infancy is routine [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/10\">",
"     10",
"    </a>",
"    ]; HBV also appears to be an uncommon cause of GCS in some developing countries, such as India [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, GCS may be the only clinical manifestation of acute HBV in infants and young children. The presence of jaundice cannot be used to indicate the need for HBV testing, since the hepatitis associated with GCS is usually anicteric. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/41/31386?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of hepatitis B virus infection in children\", section on 'Acute HBV infection'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H12\">",
"     'Other findings'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The ethnic origin, HBV carrier status of parents and family members (if known), physical status of the child, immunization status of the child, and local prevalence of HBV infection are factors to consider in making a decision about testing for HBV. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4602?source=see_link\">",
"     \"Epidemiology, transmission, and prevention of hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest the following tests for patients who are at increased risk for hepatitis B virus or who have hepatomegaly [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Liver function tests &mdash; Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, and gammaglutamyl transpeptidase (GGT).",
"     </li>",
"     <li>",
"      Hepatitis B serology &mdash; Hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAb), and hepatitis B core antibody (HBcAb). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=see_link\">",
"       \"Serologic diagnosis of hepatitis B virus infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26396461\">",
"    <span class=\"h3\">",
"     Other viruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Investigations for EBV such as polymerase chain reaction for EBV DNA in peripheral blood mononuclear cells and serologic testing are generally unnecessary, since they do not affect clinical management.",
"   </p>",
"   <p>",
"    However, identification of an etiologic agent may be indicated in immunocompromised patients",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    patients with close contact with immunocompromised patients or pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/72\">",
"     72",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Other infections'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The constellation of clinical features in GCS is usually so characteristic that the diagnosis can be made relatively easily [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/10\">",
"     10",
"    </a>",
"    ]. However, early in the course, during resolution, or in atypical cases, a number of other conditions may warrant consideration.",
"   </p>",
"   <p>",
"    Common conditions in the differential diagnosis of GCS include erythema infectiosum or other viral exanthems, erythema multiforme (early in the course), hand-foot-mouth disease, papular urticaria, scabies, diffuse lichen planus, and cutaneous drug eruptions. Less common, but important, conditions to consider in the differential diagnosis of GCS (because of the different implications for treatment, prognosis, and spread of infection) include papular purpuric gloves and socks syndrome, acrodermatitis enteropathica, Henoch-Sch&ouml;nlein purpura (IgA vasculitis), and Kawasaki disease.",
"   </p>",
"   <p>",
"    Clinical features that may help to differentiate these conditions from GCS include the onset, duration, distribution, and color of the rash; the presence and intensity of pruritus; and the involvement of the mucosa or nails [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Erythema infectiosum",
"      </strong>",
"      &minus; Erythema infectiosum (EI, also known as \"fifth disease\") is a common childhood exanthem caused by parvovirus B19. Like GCS, EI begins with nonspecific prodromal illness and acral eruption. However, the rash of EI, which begins on the cheeks (",
"      <a class=\"graphic graphic_picture graphicRef71737 \" href=\"UTD.htm?26/16/26895\">",
"       picture 2",
"      </a>",
"      ) and spreads to the extremities (",
"      <a class=\"graphic graphic_picture graphicRef75125 \" href=\"UTD.htm?11/27/11696\">",
"       picture 3",
"      </a>",
"      ), is usually macular rather than papular. By the time the rash develops, the child is no longer contagious. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22377?source=see_link&amp;anchor=H6#H6\">",
"       \"Clinical manifestations and pathogenesis of human parvovirus B19 infection\", section on 'Erythema infectiosum'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Erythema multiforme",
"      </strong>",
"      &minus; Erythema multiforme (EM) typically affects adolescents and young adults, but 20 percent of cases occur in children [",
"      <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/60\">",
"       60",
"      </a>",
"      ]. EM is often caused by herpes simplex virus or Mycoplasma infection. Although target lesions are characteristic of EM (",
"      <a class=\"graphic graphic_picture graphicRef74095 \" href=\"UTD.htm?40/61/41951\">",
"       picture 4",
"      </a>",
"      ), the lesions may be papular early in the course. Mucosal lesions are present in 25 to 50 percent of children with EM [",
"      <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/60\">",
"       60",
"      </a>",
"      ] and may help to distinguish it from GCS.",
"     </li>",
"     <li>",
"      <strong>",
"       Hand, foot, and mouth disease",
"      </strong>",
"      &minus; Hand, foot, and mouth disease (HFM) is a common childhood illness that is usually caused by the group A coxsackieviruses. HFM is characterized by fever; oral vesicles on the buccal mucosa and tongue; and peripherally distributed small, tender cutaneous lesions on the hands, feet, buttocks, and (less commonly) genitalia (",
"      <a class=\"graphic graphic_picture graphicRef58566 graphicRef71314 graphicRef53423 \" href=\"UTD.htm?19/31/19960\">",
"       picture 5A-C",
"      </a>",
"      ). It usually resolves in two to three days. The mucosal lesions and clinical course of HFM distinguish it from GCS. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/49/34585?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical manifestations and diagnosis of enterovirus and parechovirus infections\", section on 'Hand, foot, and mouth syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Scabies",
"      </strong>",
"      &minus; Scabies is an infestation of the skin by the mite Sarcoptes scabiei that results in an intensely pruritic eruption (",
"      <a class=\"graphic graphic_picture graphicRef51161 \" href=\"UTD.htm?4/4/4160\">",
"       picture 6",
"      </a>",
"      ). The degree of pruritus distinguishes scabies from GCS: GCS never itches as severely as virtually every case of scabies does. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/2/28712?source=see_link\">",
"       \"Scabies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Papular urticaria",
"      </strong>",
"      &minus; Papular urticaria (also known as insect bite-induced hypersensitivity reaction) is defined by chronic or recurrent eruptions of papules, vesicles, target lesions, or wheals caused by hypersensitivity to insect bites (eg, fleas, mosquitoes, bedbugs, mites) in children between 2 and 10 years of age. The lesions are symmetric and usually grouped in crops or clusters on exposed areas; they may take weeks to years to resolve. Management is reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28216?source=see_link&amp;anchor=H4#H4\">",
"       \"Insect bites\", section on 'Papular urticaria'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Lichen planus",
"      </strong>",
"      &minus; Diffuse lichen planus might mimic GCS in adults. Distinguishing features of lichen planus include intense pruritus, pale violet color (",
"      <a class=\"graphic graphic_picture graphicRef59807 \" href=\"UTD.htm?38/46/39652\">",
"       picture 7",
"      </a>",
"      ), frequent involvement of the mucosal surfaces, and tendency to occur on the volar surface of the wrists (",
"      <a class=\"graphic graphic_picture graphicRef50579 \" href=\"UTD.htm?2/33/2576\">",
"       picture 8",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/27/9656?source=see_link\">",
"       \"Lichen planus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Cutaneous drug eruption",
"      </strong>",
"      &minus; Cutaneous drug eruptions begin in dependent areas and generalize, often with associated mucus membrane erythema. Pruritus is the most common symptom. Blood eosinophilia may be present but is not a reliable finding. The most commonly prescribed medications (eg, antibiotics) are implicated most often.",
"      <br/>",
"      <br/>",
"      The clinical course distinguishes drug eruption from GCS. The onset of drug eruptions is almost always within two weeks of beginning a new drug, and within days of reexposure to a drug to which an individual is sensitized; chemically related compounds can cause cross reactions. Discontinuing the offending drug leads to resolution of the rash. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=see_link&amp;anchor=H3#H3\">",
"       \"Drug eruptions\", section on 'Drug-induced exanthems'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Papular purpuric gloves and socks syndrome",
"      </strong>",
"      &minus; Papular purpuric gloves and socks syndrome (PPGSS) typically occurs in young adults, but may occur in children [",
"      <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/60,73,74\">",
"       60,73,74",
"      </a>",
"      ]. It may be caused by several viruses including parvovirus B19, EBV, and CMV [",
"      <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/75,76\">",
"       75,76",
"      </a>",
"      ]. It is characterized by rapidly progressive symmetric painful swelling and erythema of hands and feet, often with a petechial or purpuric component [",
"      <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/60\">",
"       60",
"      </a>",
"      ]. There is a sharp demarcation at the wrists and ankles (",
"      <a class=\"graphic graphic_picture graphicRef51856 \" href=\"UTD.htm?31/47/32498\">",
"       picture 9",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Systemic features may include anorexia, fever, and arthralgias [",
"      <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/72\">",
"       72",
"      </a>",
"      ]. Mucosal lesions, which do not occur in GCS, are a characteristic feature of PPGSS. In contrast to patients with EI, patients with parvovirus B19-related PPGSS may remain viremic, and therefore contagious, during the exanthem [",
"      <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/60\">",
"       60",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22377?source=see_link&amp;anchor=H6#H6\">",
"       \"Clinical manifestations and pathogenesis of human parvovirus B19 infection\", section on 'Erythema infectiosum'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Acrodermatitis enteropathica",
"      </strong>",
"      &minus; Acrodermatitis enteropathica is a recessively inherited partial defect in intestinal zinc absorption. The clinical features include hyperpigmented skin lesions on the acral surfaces of the upper and the lower extremities, as well as the face and buttocks (",
"      <a class=\"graphic graphic_picture graphicRef71329 \" href=\"UTD.htm?39/34/40481\">",
"       picture 10",
"      </a>",
"      ). Acrodermatitis enteropathica is usually associated with other clinical manifestations (eg, alopecia, night blindness, diarrhea, impaired taste, growth retardation, and immune dysfunction) and has a different clinical course from GCS. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29753?source=see_link&amp;anchor=H8#H8\">",
"       \"Zinc deficiency and supplementation in children and adolescents\", section on 'Acrodermatitis enteropathica'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"      </strong>",
"      &minus; Henoch-Sch&ouml;nlein purpura (HSP, IgA vasculitis [IgAV]) is the most common form of systemic vasculitis in children. It is characterized by palpable purpura in patients with neither thrombocytopenia nor coagulopathy (",
"      <a class=\"graphic graphic_picture graphicRef63367 graphicRef72094 \" href=\"UTD.htm?26/46/27367\">",
"       picture 11A-B",
"      </a>",
"      ),",
"      <span class=\"nowrap\">",
"       arthritis/arthralgia,",
"      </span>",
"      abdominal pain, and renal disease. The clinical manifestations may develop over the course of days to weeks and may vary in their order of presentation. When present, the noncutaneous manifestations of HSP (IgAV) distinguish it from GCS. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Kawasaki disease",
"      </strong>",
"      &minus; Kawasaki disease is another common vasculitis of childhood. It is characterized by systemic inflammation manifested by fever, bilateral nonexudative conjunctivitis, erythema of the lips and oral mucosa, rash, extremity changes, and lymphadenopathy. The mucosal lesions of Kawasaki disease help to distinguish it from GCS. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12248?source=see_link\">",
"       \"Kawasaki disease: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of GCS is supportive, consisting of symptomatic treatment of pruritus and education of the parents regarding the typically benign clinical course.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Supportive care",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Pruritus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic relief for pruritus is the only necessary treatment for most children with GCS. Various treatments for pruritus in GCS have been described in observational studies; none has been studied in a randomized controlled trial.",
"   </p>",
"   <p>",
"    In our experience, topical emollients provide adequate relief for most children. We suggest topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/11/33969?source=see_link\">",
"     calamine lotion",
"    </a>",
"    for children with pruritus of moderate severity. We suggest a nocturnal dose of a systemic sedating antihistamine (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    ) for children with severe pruritus.",
"   </p>",
"   <p>",
"    Topical corticosteroids have been tried in GCS but there is no evidence that the disease course is modified by such therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/36\">",
"     36",
"    </a>",
"    ]. Nonetheless, they may be helpful in controlling pruritus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parents of children with GCS should be provided with information about the etiology, prognosis, complications, and potential spread of the eruption to other children. As a general rule, complications of GCS are rare, the course is benign, and the prognosis is good. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Etiology'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H14\">",
"     'Course'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H26\">",
"     'Control measures'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with GCS due to HBV infection should be followed-up regularly. In patients who recover from acute hepatitis B infection without progression to chronic infection, normalization of serum aminotransferases usually occurs within one to four months. Persistent elevation of serum ALT for more than six months indicates chronic hepatitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30122?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and natural history of hepatitis B virus infection\", section on 'Acute hepatitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with chronic hepatitis B infection should be referred to a pediatric gastroenterologist or hepatologist. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Referral indications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Control measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The likelihood that the eruption will spread to other children depends to some extent upon the underlying etiology. However, for most of the causative infections, children are no longer contagious once the rash appears.",
"   </p>",
"   <p>",
"    Exclusion from child-care or school is unnecessary for most children with typical GCS. Children who are hepatitis B surface antigen positive can be admitted to child-care without restrictions provided that they have no behavioral or medical risk factors (eg, aggressive behavior, biting, bleeding disorder) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23097/abstract/69\">",
"     69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/41/31386?source=see_link&amp;anchor=H18#H18\">",
"     \"Overview of hepatitis B virus infection in children\", section on 'Counseling and prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Referral indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Referral to a pediatric dermatologist may be indicated if the diagnosis is uncertain or the disease course is exceptionally prolonged (eg, longer than six months).",
"   </p>",
"   <p>",
"    Referral to a pediatric gastroenterologist or hepatologist is indicated for children with persistently elevated liver enzymes or chronic hepatitis B infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/41/31386?source=see_link\">",
"     \"Overview of hepatitis B virus infection in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gianotti-Crosti syndrome (GCS) is a symmetric papular eruption with an acral distribution (cheeks, buttocks, and extensor surfaces of the forearms and legs). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      GCS primarily affects children younger than five years, but can occur in adolescents and adults. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      GCS usually occurs in association with a viral illness. Hepatitis B virus (HBV) and Epstein-Barr virus are the most common causes. HBV is an uncommon cause of GCS in the countries where immunization of infants against HBV is routine. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although GCS has been reported to occur after the administration of various vaccines, a causal association has not been established. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Vaccines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The characteristic rash of GCS consists of symmetric monomorphous, flat-topped, pink-brown papules or papulovesicles, 1 to 10 mm in diameter, that occur on the face, buttocks, feet, and extensor aspects of forearms and legs (",
"      <a class=\"graphic graphic_picture graphicRef67780 graphicRef56024 \" href=\"UTD.htm?12/51/13111\">",
"       picture 1A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Dermatologic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Noncutaneous findings include malaise, low-grade fever, and diarrhea. Lymphadenopathy is present in 25 to 35 percent of patients, typically in the cervical, axillary, or inguinal regions. Hepatitis, when present, is usually anicteric. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Other findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of GCS is clinical. The essential features of the diagnosis include the characteristic rash, as described above, involving at least three of four acral sites (cheeks, buttocks, extensor surfaces of forearms, extensor surfaces of legs), and duration of at least 10 days. Extensive truncal lesions or scaly lesions exclude the diagnosis. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Clinical diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An etiologic diagnosis for GCS should be pursued in patients with increased risk for hepatitis B virus infection, immunocompromised patients, and patients who have close contact with immunocompromised individuals or pregnant women. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Etiologic diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The constellation of clinical features in GCS is usually characteristic. However, a number of other conditions may warrant consideration early in the course, during resolution, or in atypical cases. These include erythema infectiosum, erythema multiforme, hand-foot-mouth disease, scabies, papular urticaria, lichen planus, papular purpuric gloves and socks syndrome, acrodermatitis enteropathica, Henoch-Sch&ouml;nlein purpura (IgA vasculitis), and Kawasaki disease. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of GCS is supportive. We suggest the following supportive measures (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Topical emollients for mild pruritus",
"     </li>",
"     <li>",
"      Topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/11/33969?source=see_link\">",
"       calamine lotion",
"      </a>",
"      for moderate pruritus",
"     </li>",
"     <li>",
"      A nighttime dose of sedating antihistamine (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      ) for severe pruritus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with GCS due to HBV infection should be followed-up regularly. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Referral to a pediatric gastroenterologist or hepatologist is indicated for children with persistently elevated liver enzymes or chronic hepatitis B infection. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Referral indications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/1\">",
"      GIANOTTI F. [Report on a special case of toxic infection characterized by a desquamative erythemato-infiltrative eruption with lenticular foci and a selective localization at the extremities]. Soc Ital Dermatol Sifilogr Sezioni Interprov Soc Ital Dermatol Sifilogr 1955; 96:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/2\">",
"      CROSTI A, GIANOTTI F. [Eruptive dermatosis of probable viral origin situated on the acra]. Dermatologica 1957; 115:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/3\">",
"      Gianotti F. [Viral anicteric hepatitis in infantile papular acrodermatitis]. Epatologia 1966; 12:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/4\">",
"      Gianotti F. [Infantile papular acrodermatitis. Acrodermatitis papulosa and the infantile papulovesicular acrolocalized syndrome]. Hautarzt 1976; 27:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/5\">",
"      Gianotti F. Papular acrodermatitis of childhood and other papulo-vesicular acro-located syndromes. Br J Dermatol 1979; 100:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/6\">",
"      Claudy AL, Ortonne JP, Trepo C, Bugnon B. [Adult papular acrodermatitis (Gianotti's disease). Report of 3 cases]. Ann Dermatol Venereol 1977; 104:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/7\">",
"      Niitsuma H, Ishii M, Ojima T, et al. [A case of acute hepatitis infected with hepatitis B virus during pregnancy and complicated by Gianotti-Crosti syndrome]. Nihon Shokakibyo Gakkai Zasshi 1999; 96:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/8\">",
"      Gibbs S, Burrows N. Gianotti-Crosti syndrome in two unrelated adults. Clin Exp Dermatol 2000; 25:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/9\">",
"      Caputo R, Gelmetti C, Ermacora E, et al. Gianotti-Crosti syndrome: a retrospective analysis of 308 cases. J Am Acad Dermatol 1992; 26:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/10\">",
"      Brandt O, Abeck D, Gianotti R, Burgdorf W. Gianotti-Crosti syndrome. J Am Acad Dermatol 2006; 54:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/11\">",
"      Jindal T, Arora VK. Gianotti-crosti syndrome. Indian Pediatr 2000; 37:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/12\">",
"      Ta&iuml;eb A, Plantin P, Du Pasquier P, et al. Gianotti-Crosti syndrome: a study of 26 cases. Br J Dermatol 1986; 115:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/13\">",
"      Brown J, Rentiers P. The Gianotti-Crosti syndrome: a distrinctive exanthem. Can Med Assoc J 1969; 100:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/14\">",
"      Toda G, Ishimaru Y, Mayumi M, Oda T. Infantile papular acrodermatitis (Gianotti's disease) and intrafamilial occurence of acute hepatitis B with jaundice: age dependency of clinical manifestations of hepatitis B virus infection. J Infect Dis 1978; 138:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/15\">",
"      Ishimaru Y, Ishimaru H, Toda G, et al. An epidemic of infantile papular acrodermatitis (Gianotti's disease) in Japan associated with hepatitis-B surface antigen subtype ayw. Lancet 1976; 1:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/16\">",
"      Kanzaki S, Kanda S, Terada K, et al. Detection of hepatitis B surface antigen subtype adr in an epidemic of papular acrodermatitis of childhood (Gianotti's disease). Acta Med Okayama 1981; 35:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/17\">",
"      Baldari U, Monti A, Righini MG. An epidemic of infantile papular acrodermatitis (Gianotti-Crosti syndrome) due to Epstein-Barr virus. Dermatology 1994; 188:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/18\">",
"      Yoshida M, Tsuda N, Morihata T, et al. Five patients with localized facial eruptions associated with Gianotti-Crosti syndrome caused by primary Epstein-Barr virus infection. J Pediatr 2004; 145:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/19\">",
"      Demattei C, Zawar B, Lee A, et al. Spatial-temporal case clustering in children with Gianotti-Crosti syndrome. Systematic analysis led to the identification of a mini-epidemic. Eur J Pediat Dermatol 2006; 16:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/20\">",
"      Colombo M, Rumi MG, Sagnelli E, et al. Acute hepatitis B in children with papular acrodermatitis. Pediatr Pathol 1986; 6:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/21\">",
"      Lee S, Kim KY, Hahn CS, et al. Gianotti-Crosti syndrome associated with hepatitis B surface antigen (subtype adr). J Am Acad Dermatol 1985; 12:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/22\">",
"      Claudy AL, Ortonne JP, Trepo C, Bugnon B. Papular acrodermatitis associated with hepatitis B virus infection. Arch Dermatol 1979; 115:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/23\">",
"      Rubenstein D, Esterly NB, Fretzin D. The Gianotti-Crosti syndrome. Pediatrics 1978; 61:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/24\">",
"      Smith KJ, Skelton H. Histopathologic features seen in Gianotti-Crosti syndrome secondary to Epstein-Barr virus. J Am Acad Dermatol 2000; 43:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/25\">",
"      Maeda S, Tsuda H, Haruki S, Mitsuto I. Atypical Epstein-Barr virus infection associated with Gianotti-Crosti syndrome and Bell's palsy. Pediatr Int 1999; 41:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/26\">",
"      Drago F, Crovato F, Rebora A. Gianotti-Crosti syndrome as a presenting sign of EBV-induced acute infectious mononucleosis. Clin Exp Dermatol 1997; 22:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/27\">",
"      Hofmann B, Schuppe HC, Adams O, et al. Gianotti-Crosti syndrome associated with Epstein-Barr virus infection. Pediatr Dermatol 1997; 14:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/28\">",
"      Konno M. [An association between hepatitis-B antigen-negative infantile papular acrodermatitis and Epstein-Barr virus infection]. Hokkaido Igaku Zasshi 1989; 64:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/29\">",
"      James WD, Odom RB, Hatch MH. Gianotti-Crosti-like eruption associated with coxsackievirus A-16 infection. J Am Acad Dermatol 1982; 6:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/30\">",
"      Draelos ZK, Hansen RC, James WD. Gianotti-Crosti syndrome associated with infections other than hepatitis B. JAMA 1986; 256:2386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/31\">",
"      Tzeng GH, Hsu CY, Chen HC. Gianotti-Crosti syndrome associated with cytomegalovirus infection: report of one case. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi 1995; 36:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/32\">",
"      Berant M, Naveh Y, Weissman I. Papular acrodermatitis with cytomegalovirus hepatitis. Arch Dis Child 1983; 58:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/33\">",
"      Haki M, Tsuchida M, Kotsuji M, et al. Gianotti-Crosti syndrome associated with cytomegalovirus antigenemia after bone marrow transplantation. Bone Marrow Transplant 1997; 20:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/34\">",
"      Carrascosa JM, Just M, Ribera M, Ferr&aacute;ndiz C. Papular acrodermatitis of childhood related to poxvirus and parvovirus B19 infection. Cutis 1998; 61:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/35\">",
"      L&eacute;ger F, Callens A, Machet MC. [Parvovirus B19 primo-infection and cold agglutinins]. Ann Dermatol Venereol 1997; 124:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/36\">",
"      Boeck K, Mempel M, Schmidt T, Abeck D. Gianotti-Crosti syndrome: clinical, serologic, and therapeutic data from nine children. Cutis 1998; 62:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/37\">",
"      Hergueta Lend&iacute;nez R, Pozo Garc&iacute;a L, Alejo Garc&iacute;a A, et al. [Gianotti-Crosti syndrome due to a mixed infection produced by the mumps virus and the parainfluenza virus type 2]. An Esp Pediatr 1996; 44:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/38\">",
"      Sagi EF, Linder N, Shouval D. Papular acrodermatitis of childhood associated with hepatitis A virus infection. Pediatr Dermatol 1985; 3:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/39\">",
"      Pouillaude JM, Moulin G, Morlat C, Fran&ccedil;ois R. [Gianotti-Crosti's infantile papular acrodermatitis. Nosological relationship with viral hepatitis. A fatal outcome]. Pediatrie 1975; 30:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/40\">",
"      Di Lernia V. Gianotti-Crosti syndrome related to rotavirus infection. Pediatr Dermatol 1998; 15:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/41\">",
"      Di Lernia V, Ricci C. Skin manifestations with Rotavirus infections. Int J Dermatol 2006; 45:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/42\">",
"      de la Torre C. Gianotti-Crosti syndrome following milkers' nodules. Cutis 2004; 74:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/43\">",
"      Blauvelt A, Turner ML. Gianotti-Crosti syndrome and human immunodeficiency virus infection. Arch Dermatol 1994; 130:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/44\">",
"      Yasumoto S, Tsujita J, Imayama S, Hori Y. Case report: Gianotti-Crosti syndrome associated with human herpesvirus-6 infection. J Dermatol 1996; 23:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/45\">",
"      Chuh AA, Chan HH, Chiu SS, et al. A prospective case control study of the association of Gianotti-Crosti syndrome with human herpesvirus 6 and human herpesvirus 7 infections. Pediatr Dermatol 2002; 19:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/46\">",
"      Angoulvant N, Gr&eacute;zard P, Wolf F, et al. [Acute Mycoplasma pneumoniae infection: new cause of Gianotti Crosti syndrome]. Presse Med 2000; 29:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/47\">",
"      Manoharan S, Muir J, Williamson R. Gianotti-Crosti syndrome in an adult following recent Mycoplasma pneumoniae infection. Australas J Dermatol 2005; 46:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/48\">",
"      Silveira Cancela M, Vald&eacute;s Tasc&oacute;n F, Pita Carretero J, et al. [Neonatal papular acrodermatitis (Gianotti-Crosti) and Bartonella henselae infection]. An Esp Pediatr 2000; 52:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/49\">",
"      Baldari U, Cattonar P, Nobile C, et al. Infantile acrodermatitis of Gianotti-Crosti and Lyme borreliosis. Acta Derm Venereol 1996; 76:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/50\">",
"      Cambiaghi S, Scarabelli G, Pistritto G, Gelmetti C. Gianotti-Crosti syndrome in an adult after influenza virus vaccination. Dermatology 1995; 191:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/51\">",
"      Velangi SS, Tidman MJ. Gianotti-Crosti syndrome after measles, mumps and rubella vaccination. Br J Dermatol 1998; 139:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/52\">",
"      Andiran N, Sent&uuml;rk GB, B&uuml;k&uuml;lmez G. Combined vaccination by measles and hepatitis B vaccines: a new cause of Gianotti-Crosti syndrome. Dermatology 2002; 204:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/53\">",
"      Karaka�� M, Durdu M, Tuncer I, Cevlik F. Gianotti-Crosti syndrome in a child following hepatitis B virus vaccination. J Dermatol 2007; 34:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/54\">",
"      Erkek E, Senturk GB, Ozkaya O, B&uuml;k&uuml;lmez G. Gianotti-Crosti syndrome preceded by oral polio vaccine and followed by varicella infection. Pediatr Dermatol 2001; 18:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/55\">",
"      Kolivras A, Andr&eacute; J. Gianotti-Crosti syndrome following hepatitis A vaccination. Pediatr Dermatol 2008; 25:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/56\">",
"      Kang NG, Oh CW. Gianotti-Crosti syndrome following Japanese encephalitis vaccination. J Korean Med Sci 2003; 18:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/57\">",
"      Milbradt R, Nasemann T. [Entity of the Gianotti-Crosti's syndrome and its relation to hepatitis B infection]. Hautarzt 1975; 26:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/58\">",
"      Magyarlaki M, Drobnitsch I, Schneider I. Papular acrodermatitis of childhood (Gianotti-Crosti disease). Pediatr Dermatol 1991; 8:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/59\">",
"      Ricci G, Patrizi A, Neri I, et al. Gianotti-Crosti syndrome and allergic background. Acta Derm Venereol 2003; 83:202.",
"     </a>",
"    </li>",
"    <li>",
"     Paller AS, Mancini AJ. The exanthematous diseases of childhood. In: Hurwitz Clinical Pediatric Dermatology: A Textbook of Skin Disorders of Childhood and Adolescence, 3rd ed, WB Saunders, Philadelphia 2006. p.423.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/61\">",
"      Chuh AA. Truncal lesions do not exclude a diagnosis of Gianotti-Crosti syndrome. Australas J Dermatol 2003; 44:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/62\">",
"      Balevicien&eacute; G, Maciulevicien&eacute; R, Schwartz RA. Papular acrodermatitis of childhood: the Gianotti-Crosti syndrome. Cutis 2001; 67:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/63\">",
"      Tilly JJ, Drolet BA, Esterly NB. Lichenoid eruptions in children. J Am Acad Dermatol 2004; 51:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/64\">",
"      Spear KL, Winkelmann RK. Gianotti-Crosti syndrome. A review of ten cases not associated with hepatitis B. Arch Dermatol 1984; 120:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/65\">",
"      Chuh A, Lee A, Zawar V. The diagnostic criteria of Gianotti-Crosti syndrome: are they applicable to children in India? Pediatr Dermatol 2004; 21:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/66\">",
"      Colombo M, Gerber MA, Vernace SJ, et al. Immune response to hepatitis B virus in children with papular acrodermatitis. Gastroenterology 1977; 73:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/67\">",
"      Patrizi A, Di Lernia V, Neri I, Ricci G. An unusual case of recurrent Gianotti-Crosti syndrome. Pediatr Dermatol 1994; 11:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/68\">",
"      Gabrielsen TO, Rajka G, Rustenberg B. [Acrodermatitis papulosa eruptiva infantum as a prodrome in hepatitis B infection]. Z Hautkr 1985; 60:1793.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Hepatitis B. In: Red Book: 2009 Report of the Committee on Infectious Diseases, 28th ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2009. p.337.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/70\">",
"      Chuh AA. Diagnostic criteria for Gianotti-Crosti syndrome: a prospective case-control study for validity assessment. Cutis 2001; 68:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/71\">",
"      Zawar V, Chuh A. Gianotti-crosti syndrome in India is not associated with hepatitis B infection. Dermatology 2004; 208:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/72\">",
"      Nelson JS, Stone MS. Update on selected viral exanthems. Curr Opin Pediatr 2000; 12:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/73\">",
"      Stone MS, Murph JR. Papular-purpuric gloves and socks syndrome: a characteristic viral exanthem. Pediatrics 1993; 92:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/74\">",
"      Harms M, Feldmann R, Saurat JH. Papular-purpuric \"gloves and socks\" syndrome. J Am Acad Dermatol 1990; 23:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/75\">",
"      Hsieh MY, Huang PH. The juvenile variant of papular-purpuric gloves and socks syndrome and its association with viral infections. Br J Dermatol 2004; 151:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23097/abstract/76\">",
"      Grilli R, Izquierdo MJ, Fari&ntilde;a MC, et al. Papular-purpuric \"gloves and socks\" syndrome: polymerase chain reaction demonstration of parvovirus B19 DNA in cutaneous lesions and sera. J Am Acad Dermatol 1999; 41:793.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4040 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-200.215.4.194-8300F9CC1D-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_35_23097=[""].join("\n");
var outline_f22_35_23097=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hepatitis B virus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Epstein-Barr virus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Dermatologic findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Course",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Clinical diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Skin biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Etiologic diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26396446\">",
"      - HBV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26396461\">",
"      - Other viruses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Supportive care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Pruritus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Education",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Control measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Referral indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/4040\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/4040|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/9/10385\" title=\"picture 1A\">",
"      Gianotti Crosti",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/44/33474\" title=\"picture 1B\">",
"      Gianotti-Crosti syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/16/26895\" title=\"picture 2\">",
"      Slapped cheek rash",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/27/11696\" title=\"picture 3\">",
"      Rash in erythema infectiosum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/61/41951\" title=\"picture 4\">",
"      Erythema multiforme",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/2/13344\" title=\"picture 5A\">",
"      Hand-foot-and-mouth disease - buccal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/27/20912\" title=\"picture 5B\">",
"      Hand-foot-and-mouth disease - tongue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/22/14689\" title=\"picture 5C\">",
"      Hand-foot-and-mouth disease - foot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/4/4160\" title=\"picture 6\">",
"      Interdigital scabies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/46/39652\" title=\"picture 7\">",
"      Lichen planus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/33/2576\" title=\"picture 8\">",
"      Lichen planus wrist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/47/32498\" title=\"picture 9\">",
"      Gloves and socks syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/34/40481\" title=\"picture 10\">",
"      Acrodermatitis enteropathica",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/32/33282\" title=\"picture 11A\">",
"      Rash - Henoch Schonlein purpura IgA vasculitis A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/46/42721\" title=\"picture 11B\">",
"      Rash - Henoch Schonlein purpura IgA vasculitis B",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=related_link\">",
"      Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/49/34585?source=related_link\">",
"      Clinical manifestations and diagnosis of enterovirus and parechovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30122?source=related_link\">",
"      Clinical manifestations and natural history of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22377?source=related_link\">",
"      Clinical manifestations and pathogenesis of human parvovirus B19 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=related_link\">",
"      Clinical manifestations and treatment of Epstein-Barr virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=related_link\">",
"      Drug eruptions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4602?source=related_link\">",
"      Epidemiology, transmission, and prevention of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28216?source=related_link\">",
"      Insect bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12248?source=related_link\">",
"      Kawasaki disease: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/27/9656?source=related_link\">",
"      Lichen planus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/41/31386?source=related_link\">",
"      Overview of hepatitis B virus infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/2/28712?source=related_link\">",
"      Scabies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=related_link\">",
"      Serologic diagnosis of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29753?source=related_link\">",
"      Zinc deficiency and supplementation in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_35_23098="Immune reconstitution inflammatory syndrome";
var content_f22_35_23098=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Immune reconstitution inflammatory syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/35/23098/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/35/23098/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/35/23098/contributors\">",
"     Brian C Pien, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/35/23098/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/35/23098/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/35/23098/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/35/23098/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/35/23098/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"immune reconstitution inflammatory syndrome\" (IRIS) describes a collection of inflammatory disorders associated with paradoxical worsening of preexisting infectious processes following the initiation of highly active antiretroviral therapy (HAART) in HIV-infected individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. Preexisting infections in individuals with IRIS may have been previously diagnosed and treated or they may be subclinical and later unmasked by the host's regained capacity to mount an inflammatory response [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If immune function improves rapidly following the commencement of HAART, systemic or local inflammatory reactions may occur at the site or sites of the preexisting infection. This inflammatory reaction is usually self-limited, especially if the preexisting infection is effectively treated. However, long-term sequelae and fatal outcomes may rarely occur, particularly when neurologic structures are involved.",
"   </p>",
"   <p>",
"    This topic reviews the immunobiology, pathogenesis, clinical features, and management of IRIS. Since the clinical features are strongly linked with type and location of preexisting infection, IRIS associated with preexisting mycobacterial, cryptococcal, cytomegalovirus, Pneumocystis jirovecii, and JC virus infection will be discussed as separate entities even though the basic mechanism of illness is similar. In the absence of well-performed clinical trials, our recommendations for managing IRIS are based on clinical experience, case reports, case series, and expert opinion.",
"   </p>",
"   <p>",
"    Initiation of HAART is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many synonyms exist for IRIS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/2,8,9\">",
"     2,8,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Immune recovery disease",
"     </li>",
"     <li>",
"      Immune reconstitution disease",
"     </li>",
"     <li>",
"      Immune reconstitution syndrome",
"     </li>",
"     <li>",
"      Immune restoration disease",
"     </li>",
"     <li>",
"      Immune rebound illness",
"     </li>",
"     <li>",
"      Steroid-withdrawal disease",
"     </li>",
"     <li>",
"      Immunorestitution disease",
"     </li>",
"     <li>",
"      Immune response reactions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Paradoxical inflammatory syndromes similar to those seen in HIV-infected patients have also been described in non-HIV-infected patients following treatment for tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/10-13\">",
"     10-13",
"    </a>",
"    ] or lepromatous leprosy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/14\">",
"     14",
"    </a>",
"    ]. Similar illnesses have also occurred in some non-HIV-infected patients following corticosteroid withdrawal, discontinuation of anti-tumor necrosis factor alpha therapy, recovery of neutropenia after cytotoxic chemotherapy, withdrawal of immunosuppression in transplant recipients infected with Cryptococcus neoformans, and engraftment of stem cell transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/8,15,16\">",
"     8,15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     IMMUNOBIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV infection produces both quantitative and qualitative time-dependent deleterious effects on the immune system. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/34/5674?source=see_link\">",
"     \"Immunology of HIV-1 infection\"",
"    </a>",
"    .) The likelihood and severity of IRIS correlates with two interrelated factors: 1) the extent of CD4+ T cell immune suppression prior to the initiation of highly active antiretroviral therapy (HAART) and 2) the degree of viral suppression and immune recovery following the initiation of HAART.",
"   </p>",
"   <p>",
"    As the half-life of HIV is generally between one and four days, HAART may produce a greater than 90 percent reduction in the overall HIV viral burden within one to two weeks of starting treatment. This decline in viral load usually persists during the next 8 to 12 weeks and then stabilizes. An increase in immune effector cells occurs in inverse proportion to the fall in HIV viral load in most treated individuals.",
"   </p>",
"   <p>",
"    The typical recovery of CD4+ T lymphocyte count following HAART is biphasic [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. A rapid increase in CD4+ cells occurs during the first three to six months of HAART. This initial rise is mainly due to an increase in the numbers of CD45RO+ memory T cells and is presumed to be due to a combination of decreased lymphocyte apoptosis and simultaneous redistribution of lymphocytes from peripheral lymphoid tissues into the circulation. Thereafter, a slower increase of predominately naive CD4+ T cells (CD45RA+, CD62L+) occurs in most treated individuals. This secondary increase in CD4+ T cells is thought to be due to expansion of T cell clones produced by the thymus prior to its age-related functional decline",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    occurs secondary to thymopoiesis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. CD8+ T lymphocytes also increase rapidly after the initiation of HAART. However, the total numbers of CD8+ T lymphocytes eventually stabilize as memory CD8+ cells subsequently decline and are replaced by naive CD8+ T lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increases in T lymphocytes after initiation of HAART are also accompanied by increased in vitro lymphocyte proliferation responses, increased markers of immune activation, and pathogen-specific delayed hypersensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/18,19,23,24\">",
"     18,19,23,24",
"    </a>",
"    ]. As an example, one group of investigators studying a small group of HIV-infected patients demonstrated that inducible lymphocyte proliferation increased almost threefold after three weeks of HAART, ultimately rose fourfold, then stabilized for the next two years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/18\">",
"     18",
"    </a>",
"    ]. In vitro lymphocyte proliferation against Candida antigens as well as increases in in vitro stimulation indices with CMV antigens and tuberculin also typically occur after initiation of HAART in HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/19,23\">",
"     19,23",
"    </a>",
"    ]. Another study demonstrated that 90 percent of HIV-infected patients had cutaneous anergy prior to starting HAART; 12 weeks later, 30 percent of these patients had recovered their ability to respond to skin test antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC CRITERIA FOR IRIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no universally agreed-upon definition for IRIS. However, it is generally accepted that the diagnosis of IRIS requires the worsening of a recognized (&ldquo;paradoxical&rdquo; IRIS) or unrecognized pre-existing infection (&ldquo;unmasking&rdquo; IRIS) in the setting of improving immunologic function [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Most or all of the following features should be present in order to make the diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of AIDS with a low pretreatment CD4 count (often less than 100",
"      <span class=\"nowrap\">",
"       cells/microL)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. One important exception to this general rule is tuberculosis. IRIS secondary to preexisting M. tuberculosis infection may occur in individuals with CD4 counts &gt;200.",
"     </li>",
"     <li>",
"      A positive virologic and immunological response to ART [",
"      <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/29,30\">",
"       29,30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The absence of evidence of drug-resistant infection, bacterial superinfection, drug allergy or other adverse drug reactions, patient noncompliance, or reduced drug levels due to drug-drug interactions or malabsorption after appropriate evaluation for the clinical presentation.",
"     </li>",
"     <li>",
"      The presence of clinical manifestations consistent with an inflammatory condition",
"     </li>",
"     <li>",
"      A temporal association between HAART initiation and the onset of clinical features of illness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One prospective study found that patients developed IRIS within a median of 48 days (29 to 99 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When a diagnosis of IRIS is considered highly likely, further or repeated invasive diagnostic procedures to locate an occult infection may be reasonably delayed, deferred, or altogether avoided. However, localized drainage (with appropriate cultures) is indicated for symptomatic relief of mycobacterial lymphadenitis as well as for diagnostic purposes.",
"   </p>",
"   <p>",
"    The hypersensitivity reaction seen with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    may be difficult to distinguish from systemic IRIS, such as that seen with M. avium complex (MAC). Symptoms of abacavir hypersensitivity typically get worse after each dose of the medication and then improve prior to the next dose, but with a trend towards worsening over time. Genetic testing for HLA B*5701 can help distinguish abacavir hypersensitivity from IRIS. Management of abacavir hypersensitivity is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21049?source=see_link\">",
"     \"Abacavir hypersensitivity reaction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of IRIS is broad and includes progression of the initial OI (eg, due to antimicrobial resistance and nonadherence), development of a new OI, or drug toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early retrospective case series studies suggested that up to 30 percent of ART responders developed one or more inflammatory syndromes consistent with IRIS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/2,27\">",
"     2,27",
"    </a>",
"    ]. Subsequent data have suggested that the incidence is probably much lower.",
"   </p>",
"   <p>",
"    Data from prospective and retrospective studies suggest that the incidence of IRIS following ART is largely dependent on two things: 1) the likelihood of a preexisting opportunistic infection and 2) the likelihood of a viral and immunologic response to ART. The following studies illustrate the incidence of cases that have been reported in a variety of settings and the range of infections that have been described:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a systematic review and meta-analysis of about 13,000 HIV patients, 13 percent of subjects developed IRIS [",
"      <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/32\">",
"       32",
"      </a>",
"      ]. Some of the most common diagnoses included tuberculosis, herpes infections, cryptococcal meningitis, CMV retinitis, and PML.",
"     </li>",
"     <li>",
"      In a prospective trial that evaluated the optimum management of patients with AIDS-related opportunistic infections (A5164), the incidence of IRIS was 7.6 percent, which occurred a median of 33 days after the initiation of ART [",
"      <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/26\">",
"       26",
"      </a>",
"      ]. In another prospective cohort study in South Africa, an overall incidence rate of 25 cases of IRIS per 100 patient-years was reported, affecting approximately 10 percent of subjects [",
"      <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2253293\">",
"    <span class=\"h1\">",
"     PATHOGENS ASSOCIATED WITH IRIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many different pathogens have been associated with the development of IRIS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/3,31,33-44\">",
"     3,31,33-44",
"    </a>",
"    ]. The leading pathogens include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mycobacterium tuberculosis",
"     </li>",
"     <li>",
"      Mycobacterium avium complex",
"     </li>",
"     <li>",
"      Cytomegalovirus",
"     </li>",
"     <li>",
"      Cryptococcus",
"     </li>",
"     <li>",
"      Pneumocystis",
"     </li>",
"     <li>",
"      Herpes simplex",
"     </li>",
"     <li>",
"      Hepatitis B",
"     </li>",
"     <li>",
"      Human herpes virus 8 (associated with Kaposi sarcoma)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some case reports have also documented IRIS associated with: hepatitis C virus, parvovirus B19 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/33\">",
"     33",
"    </a>",
"    ], herpes simplex, Bartonella henselae, Histoplasma capsulatum [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/34\">",
"     34",
"    </a>",
"    ], dermatophytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/35\">",
"     35",
"    </a>",
"    ], leprosy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/36-38\">",
"     36-38",
"    </a>",
"    ], bacillus Calmette-Gu&eacute;rin (BCG) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/39\">",
"     39",
"    </a>",
"    ], Penicillium marneffei [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/40\">",
"     40",
"    </a>",
"    ], Schistosoma mansoni [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/41\">",
"     41",
"    </a>",
"    ], and molluscum contagiosum virus. In addition, some patients with Kaposi sarcoma have developed an IRIS-like syndrome when HAART was initiated [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/31,43,44\">",
"     31,43,44",
"    </a>",
"    ], and other patients have developed Grave's thyrotoxicosis or recurrence of sarcoidosis after starting HAART.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several retrospective studies have demonstrated that lower CD4 cell counts at the time of treatment initiation increase the risk of developing IRIS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/2,27,28,31\">",
"     2,27,28,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequent data suggest that the response to ART also plays an important role in predicting risk. In one prospective trial of 282 patients with AIDS-related OIs, the risk of IRIS was related to low CD4 counts at baseline (HR = 0.79 per 10 additional CD4",
"    <span class=\"nowrap\">",
"     cells/mm3;",
"    </span>",
"    95% CI 0.65, 0.97) and degree of immunologic improvement on ART (HR = 1.08 per additional 10 CD4",
"    <span class=\"nowrap\">",
"     cells/mm3;",
"    </span>",
"    95% CI 1.03, 1.13) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/26\">",
"     26",
"    </a>",
"    ]. Similarly, the risk of IRIS was also associated with a higher level of viremia at baseline (HR = 2.5 per 1 log increase in HIV RNA; 95% CI 1.19, 5.21) and the degree of viral decline on ART (HR = 0.43 per 1 log increase in HIV RNA; 95% CI 0.24, 0.78). Fungal infections (except for Pneumocystis) were also associated with an increased risk of IRIS in the multivariate analysis.",
"   </p>",
"   <p>",
"    One case-control study demonstrated that the risk of developing IRIS was associated with use of a \"boosted\" protease inhibitor, a CD4 count nadir less than 100",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    and a plasma HIV RNA decline of more than 2.5 logs on ART [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/28\">",
"     28",
"    </a>",
"    ]. Protease inhibitors have immunomodulatory effects on T cell lymphoproliferation and apoptosis; they also enhance macrophage production of proinflammatory cytokines, (eg, interleukin-6 and tumor necrosis factor alpha). These in vitro observations suggest that there may be multiple mechanisms through which protease inhibitors may increase the risk of IRIS apart from HIV suppression itself. However, a subsequent prospective trial did not find any difference in incidence of IRIS events based on whether patients took a protease inhibitor-based ART regimen or a nonnucleoside reverse transcriptase inhibitor-based regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of IRIS are strongly related to the type and location of preexisting opportunistic infection. Furthermore, preexisting infections may or may not be clinically apparent prior to the initiation of ART. Since the clinical features of IRIS vary so widely, IRIS due to specific pathogens are discussed in the sections that follow. However, a few generalizations can be made. Symptoms of IRIS can be localized or systemic. About three-fourths of patients with mycobacterial or cryptococcal-related immune reconstitution syndromes develop fever [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/8\">",
"     8",
"    </a>",
"    ]. In contrast, fever occurs infrequently in IRIS related to previously recognized or subclinical infection with cytomegalovirus. The median time to IRIS diagnosis in one trial was 33 days [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/26\">",
"     26",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     IRIS associated with mycobacterial infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the widespread emergence of HIV infection, an IRIS-like paradoxical inflammatory response was known to occur in some patients treated for tuberculosis (TB) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/10-12,45\">",
"     10-12,45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17272?source=see_link\">",
"     \"Monitoring the HIV-infected patient on antituberculous medications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The paradoxical reaction that follows the commencement of anti-tuberculosis therapy for pulmonary TB is usually characterized by fever, malaise, weight loss, and worsening respiratory symptoms. Transient worsening of radiographic abnormalities, including new parenchymal opacities and progressive intrathoracic lymph node enlargement may also occur in such patients. Rarely pulmonary involvement may progress to severe respiratory compromise and adult respiratory distress syndrome. With more widespread use of ART in areas with a high prevalence of TB, this reaction is likely to become more common [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with extrapulmonary M. tuberculosis (MTb) infection may develop worsening lymphadenitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/10,47,48\">",
"     10,47,48",
"    </a>",
"    ], new pleural effusions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/48-50\">",
"     48-50",
"    </a>",
"    ], the reappearance of fever with new infiltrates [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/51\">",
"     51",
"    </a>",
"    ], expansion of preexisting intracranial tuberculomas [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/11,48,52-54\">",
"     11,48,52-54",
"    </a>",
"    ], or worsening of meningitis or radiculomyelopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/54\">",
"     54",
"    </a>",
"    ] after anti-tuberculosis therapy is begun. Aspiration of fluctuant lymph nodes often reveals purulent material, but mycobacterial cultures are typically sterile and acid fast stains yield relatively few or no organisms. When MTb is recovered in patients with paradoxical reactions, these organisms usually have not developed new antituberculous drug resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/45\">",
"     45",
"    </a>",
"    ]. IRIS in HIV-infected patients with TB meningitis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/2/28713?source=see_link&amp;anchor=H7479621#H7479621\">",
"     \"Central nervous system tuberculosis\", section on 'HIV infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanism for paradoxical reactions is not well understood, but it appears to be immune mediated. Changes in the ability to respond to tuberculin proteins occur in some patients following the initiation of antituberculous therapy. For example, in one study 74 percent of patients who were initially anergic had reversion of their previously negative tuberculin skin tests within two weeks of starting antituberculous therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/55\">",
"     55",
"    </a>",
"    ]. Also, the incidence of paradoxical reactions in non-HIV-infected patients may be higher in patients who develop TB while receiving the immunomodulator",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Paradoxical clinical deterioration of non-HIV infected patients with pulmonary TB following the initiation of anti-tuberculous therapy is assumed to be a self-limited phenomenon in most cases. Nonsteroidal anti-inflammatory agents can be used for mild symptoms. However, several controlled studies of patients with moderate to severe manifestations of IRIS have suggested that adjunctive corticosteroid therapy (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    dosed at approximately 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    body weight) results in faster short-term symptomatic improvement and radiographic resolution [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]; corticosteroid dosing is gradually reduced after one to two weeks to decrease the risk of adverse events.",
"   </p>",
"   <p>",
"    The incidence of paradoxical worsening associated with pulmonary TB is higher in HIV-infected individuals following HAART initiation compared with those who are not coinfected with HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. As an example, in a prospective study paradoxical inflammatory reactions were documented in 12 of 33 patients (36 percent) coinfected with HIV and treated with HAART, but similar reactions occurred in only 1 of 55 patients (2 percent) without HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/61\">",
"     61",
"    </a>",
"    ]. A retrospective review found severe transient worsening of chest radiograph appearance in 7 of 31 patients (23 percent) who were coinfected with HIV and MTb and treated for both, and in 2 of 56 patients (4 percent; 26 patients with HIV coinfection and 30 patients without HIV) who were only receiving therapy for TB [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/62\">",
"     62",
"    </a>",
"    ]. In a retrospective cohort of 144 HIV patients with TB coinfection, 11 (8 percent) had a paradoxical reaction after a median time of 47 days following HAART initiation and an incidence rate of 15 cases per 100 patient-years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who are coinfected with MTb and HIV may also develop IRIS that manifests as tuberculous lymphadenitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/64\">",
"     64",
"    </a>",
"    ], cutaneous lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/61\">",
"     61",
"    </a>",
"    ], peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/65\">",
"     65",
"    </a>",
"    ], epididymitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/65\">",
"     65",
"    </a>",
"    ], bowel perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/66\">",
"     66",
"    </a>",
"    ], or granulomatous nephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/67\">",
"     67",
"    </a>",
"    ]. The time interval from initiation of HAART to the onset of IRIS associated with MTb infection has varied from 10 to 180 days [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/3\">",
"     3",
"    </a>",
"    ], but tends to occur within the first 60 days of starting HAART therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/6,48\">",
"     6,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients coinfected with HIV and M. avium complex (MAC) may also develop inflammatory reactions following the initiation of antiretroviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/68-71\">",
"     68-71",
"    </a>",
"    ]. In the majority of cases, IRIS due to MAC manifests as fever and painful lymphadenitis that occurs one to eight weeks after HAART is commenced [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. Individual case reports or small case series also exist describing IRIS syndrome manifesting as necrotic subcutaneous nodules, osteomyelitis, bursitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/1\">",
"     1",
"    </a>",
"    ], granulomatous hepatitis, paravertebral abscesses [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/3\">",
"     3",
"    </a>",
"    ], brain abscess [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/73\">",
"     73",
"    </a>",
"    ], worsening lung infiltrates, or diffuse intestinal involvement presenting with abdominal pain [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/74\">",
"     74",
"    </a>",
"    ]. In two reviews, onset occurred within one month of starting HAART in the majority of patients who developed MAC-related IRIS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/3,70\">",
"     3,70",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_picture graphicRef68538 \" href=\"UTD.htm?41/44/42688\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69627 \" href=\"UTD.htm?19/16/19717\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef70875 \" href=\"UTD.htm?10/61/11216\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The majority of patients with IRIS due to treated MAC infection have negative blood and bone marrow cultures. In contrast to findings in patients with AIDS and untreated MAC infection, biopsies of lymph nodes of patients with IRIS secondary to MAC usually reveal well-formed granulomas with relatively few visible organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     IRIS associated with preexisting cryptococcal infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-infected patients previously infected with Cryptococcus spp. may develop symptoms of IRIS localized to the central nervous system (CNS) or the lungs [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/76\">",
"     76",
"    </a>",
"    ]. Symptoms often occur within two months after commencement of therapy, but may be delayed for more than six months [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/76-78\">",
"     76-78",
"    </a>",
"    ]. Despite the use of concurrent antifungal therapy, patients with preexisting cryptococcal meningoencephalitis may develop fever, increased headache, nausea, eye pain, photophobia, and nuchal rigidity following the initiation of HAART [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At the time of initial cryptococcal meningoencephalitis diagnosis, a paucity of CSF inflammation (eg, WBC &lt;25",
"    <span class=\"nowrap\">",
"     cells/microL)",
"    </span>",
"    have been associated with development of IRIS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/80\">",
"     80",
"    </a>",
"    ]. Conversely, follow-up lumbar puncture in patients with IRIS associated with cryptococcal meningitis often reveals more inflammatory cells than were found prior to the initiation of antifungal therapy and HAART; however, cultures usually remain sterile. One retrospective study found that compared with classic forms of AIDS-related cryptococcal meningitis, patients with IRIS-related cryptococcal meningitis had significantly higher opening pressures, CSF WBC counts (56 versus 12",
"    <span class=\"nowrap\">",
"     cells/microL),",
"    </span>",
"    CD4 cell counts, and lower HIV viral loads [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/81,82\">",
"     81,82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HIV-infected patients with preexisting cryptococcal pulmonary infection may develop cavitary lung lesions, hypoxia, respiratory failure, and ARDS following the initiation of HAART [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/3,83\">",
"     3,83",
"    </a>",
"    ]. Rarely, patients with disseminated cryptococcal infections may develop mediastinal lymphadenitis, hypercalcemia, and cutaneous abscesses as part of the IRIS syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/83,84\">",
"     83,84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     IRIS associated with cytomegalovirus",
"    </span>",
"    &nbsp;&mdash;&nbsp;IRIS due to prior cytomegalovirus (CMV) infection has been termed \"immune recovery uveitis\" (IRU) or \"immune recovery vitritis\" by various investigators [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. IRIS has been reported in 16 to 63 percent of HIV-infected patients with CMV retinitis following the initiation of HAART [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/29,86,87\">",
"     29,86,87",
"    </a>",
"    ]. In one study the median time to IRU following HAART initiation was 43 weeks, but onset can occur as early as four weeks or as late as four years in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/85,86\">",
"     85,86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IRU may manifest with some or all of the following: painless floaters, blurred vision, photopia (the sensation of flashing lights), decreased visual acuity, or ocular pain. Patients with IRIS due to preexisting CMV retinitis may develop extensive vitritis, papillitis, cataracts, epiretinal membrane formation, and cystoid macular edema. Although visual loss is most commonly due to macular edema, patients may develop proliferative vitreoretinopathy, spontaneous vitreal hemorrhage, and vitreomacular traction leading to retinal detachment.",
"   </p>",
"   <p>",
"    Fundoscopic examination of such patients reveals an intense inflammatory reaction far beyond that usually seen with CMV retinitis (which usually manifests as necrosis of the retina with minimal intraocular inflammation) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/88\">",
"     88",
"    </a>",
"    ]. Despite treatment efforts, a significant proportion of patients with IRU may develop a chronic inflammatory condition resulting in significant visual complications lasting for months or years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although CMV-associated IRIS usually manifests as IRU or worsening retinitis, preexisting CMV infection may rarely result in IRIS manifesting as pneumonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/90\">",
"     90",
"    </a>",
"    ], colitis, pancreatitis, or submandibular inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/91\">",
"     91",
"    </a>",
"    ]. Some cases of CMV-associated IRIS have occurred in HIV-infected patients with absolute CD4 counts above 100",
"    <span class=\"nowrap\">",
"     cells/mm3,",
"    </span>",
"    a remarkable finding in contrast to that seen in HIV-infected patients during the pre-HAART era when &lt;1 percent of patients with CD4 counts above 100",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    developed symptoms attributable to CMV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     IRIS due to preexisting infection with JC virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-infected patients co-infected with JC virus may develop progressive multifocal leukoencephalopathy (PML) after CD4 cell counts drop below",
"    <span class=\"nowrap\">",
"     200/microL.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/7/44151?source=see_link\">",
"     \"Clinical manifestations and diagnosis of JC, BK, and other polyomavirus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although most HIV-infected patients with PML improve following the initiation of HAART, about 10 to 20 percent of patients may develop new or worsening neurologic symptoms associated with enlarging CNS lesions that show secondary enhancement after infusion of contrast agents (a finding not typically present in AIDS patients with PML) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/93-95\">",
"     93-95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most cases of IRIS associated with JC virus infections occur three to six weeks after HAART is begun [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/93\">",
"     93",
"    </a>",
"    ]. Biopsy in such cases reveals extensive demyelination and surrounding inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/96,97\">",
"     96,97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients generally experience clinical improvement or stabilization after three to six months of continued HAART, but IRIS associated with JC virus may directly or indirectly result in a fatal outcome despite an excellent virologic response to HAART, even if adjunctive corticosteroid therapy is used [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/93,94,97,98\">",
"     93,94,97,98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     IRIS associated with Pneumocystis jirovecii infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many HIV-infected patients with P. jirovecii pneumonia (PCP) develop a paradoxical inflammatory response following the initiation of antimicrobial therapy directed against P. carinii. For this reason adjunctive corticosteroids are routinely used in patients with moderate to severe disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27593?source=see_link\">",
"     \"Treatment of Pneumocystis infection in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IRIS associated with P. carinii infection in patients with advanced HIV infection results in similar symptoms, but IRIS can be suspected when the onset correlates more closely with HAART initiation than with treatment for PCP.",
"   </p>",
"   <p>",
"    One to three weeks after initiating HAART, some patients who were previously treated with both antipneumocystis therapy and corticosteroids and responded well go on to develop IRIS manifesting as recurrent fever, increased cough, chest discomfort, dyspnea, hypoxia, and progressive radiographic pulmonary opacification. Repeat bronchoscopy may reveal large numbers of inflammatory cells in bronchoalveolar lavage fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/99-101\">",
"     99-101",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     IRIS associated with herpes zoster",
"    </span>",
"    &nbsp;&mdash;&nbsp;A study that compared the incidence of symptomatic varicella-zoster virus (VZV) infection in HIV-infected patients with and without concurrent antiretroviral therapy found that symptomatic herpes zoster occurred two to nine times as often in HIV-infected patients treated with HAART as compared to HIV-infected patients who did not receive HAART.",
"   </p>",
"   <p>",
"    Almost all such cases are limited to a localized dermatomal distribution and respond well to oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    . Some patients with preexisting ocular infection with VZV develop striking keratitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    iritis within the first one to four months following the initiation of HAART [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     IRIS associated with hepatitis B and C",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coinfection with HIV alters the natural history of patients with hepatitis B and C virus infections even in the absence of treatment for HIV. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7033?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30218?source=see_link\">",
"     \"Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptoms and laboratory abnormalities suggesting worsening hepatitis may occur in patients coinfected with HCV or HBV following HAART [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/103-107\">",
"     103-107",
"    </a>",
"    ]. Affected patients typically have elevated serum liver enzymes accompanied by fevers, night sweats, anorexia, nausea, fatigue, tender hepatomegaly, and jaundice. Some patients have developed symmetric inflammatory polyarthralgias, sometimes associated with mixed cryoglobulinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/108\">",
"     108",
"    </a>",
"    ], while others have developed porphyria cutanea tarda [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/105\">",
"     105",
"    </a>",
"    ]. IRIS associated with hepatitis viruses B and C usually occurs within two to eight weeks of initiation of HAART but onset may be delayed for up to nine months.",
"   </p>",
"   <p>",
"    The incidence of clinical hepatitis among HAART responders who are coinfected with HBV or HCV is estimated to be 1 to 5 percent. Because elevated liver enzymes in coinfected patients treated with HAART can be due to a variety of causes such as hepatotoxic drug effects (as can be seen with protease inhibitors or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    ), drug-induced lactic acidosis, withdrawal of antiviral therapy in a patient with underlying HBV, Kaposi sarcoma, or other infectious causes such as new infection with other hepatotrophic viruses, it is often difficult to establish a definitive diagnosis of IRIS. However, in cases of presumed IRIS due to preexisting hepatitis B or C viruses, patients undergoing liver biopsy show dramatic liver necrosis and inflammatory activity with markedly increased CD8+ T cell infiltration in the absence of microbiological evidence of infection with other infectious agents that cause hepatic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/103,107\">",
"     103,107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a few cases, patients with symptomatic hepatitis due to IRIS related to HCV or HBV infection underwent documented virus-specific seroconversion. In the cases involving HCV, these patients were often previously undiagnosed with HCV because they tested antibody-negative. When stored serum (which was drawn one to two years prior to HAART initiation) was retrospectively tested for HCV by PCR, it revealed detectable levels of HCV RNA, indicating prior subclinical infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/105\">",
"     105",
"    </a>",
"    ]. In at least one case of IRIS associated with a known chronic HBV carrier, hepatitis B core antibody and hepatitis B e antibody titers significantly increased and hepatitis B e antigen was cleared from the serum [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognosis of HBV and HCV-related IRIS appears to depend in part on the underlying hepatic functional reserve. The treatment of the HIV-infected patient with underlying hepatitis C or hepatitis B infection is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/38/18026?source=see_link\">",
"     \"Treatment of hepatitis C virus infection in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16185?source=see_link\">",
"     \"Treatment of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Leishmaniasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cases of IRIS involving visceral and cutaneous manifestations of leishmaniasis have been reported in patients with advanced AIDS who initiated HAART [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/109\">",
"     109",
"    </a>",
"    ]. Immunologic reconstitution led to activation of latent disease resulting in severe infiltrative plaques and ulcers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Kaposi sarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been reports of patients with Kaposi sarcoma (KS) developing an IRIS-like syndrome that can include rapid clinical progression of KS when ART is initiated [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. In some resource-limited settings where KS is relatively more common, this clinical issue has taken on greater importance with the greater availability of potent ART.",
"   </p>",
"   <p>",
"    One study in Uganda evaluated 55 patients with cutaneous KS who were participating in a randomized trial of two different ART regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/110\">",
"     110",
"    </a>",
"    ]. Over a 12-week period, a variety of clinical changes were noted, including marked lesional swelling, increased tenderness, and peripheral edema. Although most of these findings resolved spontaneously on continued ART, a minority of patients with suspected pulmonary involvement required chemotherapy; two patients died.",
"   </p>",
"   <p>",
"    In the United States, fatal cases of KS-related IRIS have been reported, particularly among those with visceral involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/111,112\">",
"     111,112",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/37/18009?source=see_link\">",
"     \"AIDS-related Kaposi sarcoma: Staging and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Miscellaneous syndromes possibly associated with IRIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A few autoimmune and other noninfectious conditions may dramatically worsen or appear after HAART is begun, suggesting that inflammation induced by an IRIS-like syndrome is responsible. Whether such associations represent a casual or a coincidental finding is unproven at present.",
"   </p>",
"   <p>",
"    Sarcoidosis has occurred in some HIV-infected patients soon after initiation of HAART [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/113-115\">",
"     113-115",
"    </a>",
"    ]. Prior to the introduction of HAART, progressive sarcoidosis and advanced HIV infection were considered to be divergent disease processes because CD4+ T cells (which are usually depleted in patients with advanced HIV infection) were believed to be essential for granuloma formation. However the occurrence of sarcoidosis immediately following HAART suggests that immune reconstitution may \"trigger\" the reactivation or appearance of preexisting subclinical sarcoidosis. Indeed some but not all patients with IRIS-associated sarcoidosis had preexisting known sarcoidosis that became inactive years earlier. IRIS-associated sarcoidosis typically occurs &gt;12 months after HAART commencement. Most reported cases have responded to corticosteroid therapy.",
"   </p>",
"   <p>",
"    Several authors have reported that autoimmune thyroiditis and Graves' disease can appear soon after starting HAART [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/116-118\">",
"     116-118",
"    </a>",
"    ]. Although the mechanism for this phenomenon is not fully understood, expansion of the T cell receptor repertoire along with pathologic immune dysregulation may lead to formation of autoreactive immune cells that in turn produce anti-thyrotropin receptor and other autoantibodies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should generally be treated for the underlying opportunistic infection as soon as possible. The timing of antiretroviral therapy, relative to initiation of treatment for the opportunistic infection, is addressed below. The potential utility of adjuvant therapies for IRIS is also discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Timing of antiretroviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The timing of ART relative to treatment of the underlying opportunistic infection was somewhat controversial in the past. Some experts supported early ART in hopes of reducing the risk of AIDS-related morbidity and mortality. Advantages of prompt initiation of ART include earlier immunologic recovery, which in turn may contribute to faster resolution of the OI. Other experts proposed deferring ART in order to decrease the risk of IRIS. These experts cited the following reasons for this approach: additive toxicities of multiple therapeutic agents, drug interactions, and the problem of differentiating IRIS from other comorbidities [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A large body of evidence suggests that although IRIS may occur, the early initiation of ART should be offered rather than deferred therapy, because early ART decreases the risk of overall mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/26,119\">",
"     26,119",
"    </a>",
"    ]. A randomized phase IV trial (AIDS Clinical Trial Group ACTG 5164) randomly assigned 282 patients to immediate (within 14 days) or deferred ART (&gt;28 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/119\">",
"     119",
"    </a>",
"    ]. Randomization was stratified by CD4 count (&lt; or &ge;50 cells) and by opportunistic infection. Patients with tuberculosis were excluded.",
"   </p>",
"   <p>",
"    The combined primary endpoint at 48 weeks included clinical and laboratory outcomes: AIDS",
"    <span class=\"nowrap\">",
"     progression/death",
"    </span>",
"    and HIV RNA suppression. The most common opportunistic infections included Pneumocystis (63 percent) and cryptococcal meningitis (13 percent). Preliminary results are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients in the immediate and deferred arms started ART a median of 12 and 45 days, respectively, after treatment for the opportunistic infection had been initiated.",
"     </li>",
"     <li>",
"      There were no significant differences between the immediate and deferred ART arms in the primary endpoint, which included both clinical and virologic outcomes.",
"     </li>",
"     <li>",
"      However, the patients assigned to the immediate ART arm had significantly fewer",
"      <span class=\"nowrap\">",
"       deaths/AIDS",
"      </span>",
"      progression and a shorter time to achieving a CD4 count &gt;50 cells (3.9 versus 8.1 weeks) compared to patients in the deferred ART arm.",
"     </li>",
"     <li>",
"      There were no significant differences in grade 3 or 4 adverse events, adherence, hospitalizations, or risk of IRIS between the two arms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In another prospective study among 559 treatment-naive patients initiating ART in Kampala, Uganda, 17 percent died over a 36-month time period [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/120\">",
"     120",
"    </a>",
"    ]. Most of the deaths (73 percent) occurred during the first three months after initiating ART; only 7 percent of these deaths could be attributed to IRIS.",
"   </p>",
"   <p>",
"    Based on these data, the International AIDS Society-USA Panel and the Department of Health and Human Services (DHHS) HIV treatment guidelines both recommend that absent any contraindications, ART should be initiated within approximately two weeks after initiation of OI therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/57,121,122\">",
"     57,121,122",
"    </a>",
"    ]. The choice of ART will be strongly influenced by potential drug interactions with the therapeutic agents given for the OI. After initiation of ART, clinicians should be alert to potential IRIS events.",
"   </p>",
"   <p>",
"    The management of patients with underlying TB is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17272?source=see_link\">",
"     \"Monitoring the HIV-infected patient on antituberculous medications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Options for management of IRIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the incidence of IRIS has been reported to be up to 30 percent in some case series. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Incidence'",
"    </a>",
"    above.) When IRIS does occur, there are several options for management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Continuation of ART when IRIS occurs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Published clinical experience suggests that it is reasonable to continue ART in the majority of cases. In patients with IRIS that is not life-threatening and that is not placing the patient at risk for permanent sequelae, mild or moderate symptoms may be tolerable and patients can be reassured that symptoms will resolve over time.",
"   </p>",
"   <p>",
"    However, ART should be discontinued and hospitalization may be required in patients who experience life-threatening IRIS or in whom localized symptoms threaten to cause permanent sequelae (eg, airway obstruction from an enlarging mass) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/31\">",
"     31",
"    </a>",
"    ]. These patients can be treated for a period of time for their underlying infection before resuming ART again. This may not be an option in conditions (such as PML) that do not have other effective therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Role of anti-inflammatory agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are no controlled trials evaluating the role of corticosteroids or non-steroidal anti-inflammatory agents (NSAIDS), multiple case reports and case series suggest these ancillary agents may have efficacy in decreasing the inflammatory response associated with IRIS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anti-inflammatory agents may be particularly helpful in the setting of obstructive mass lesions (ie, expanding cervical lymph node secondary to MAI). Use of antiinflammatory agents, particularly corticosteroids, must be weighed against potential risks and side effects. When we choose to treat with corticosteroids, we initiate therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    at a dose of 1",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    (maximal dose 60 to 80 mg). A rapid taper over a 10 to 14 day period, while monitoring for recurrence of clinical symptoms, is recommended over the ensuing weeks to months.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    (8 to 16",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    divided into twice daily dosing) can also be used.",
"   </p>",
"   <p>",
"    The management of IRIS in TB-infected HIV-seropositive patients is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17272?source=see_link\">",
"     \"Monitoring the HIV-infected patient on antituberculous medications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Options for managing specific etiologies of IRIS are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef65960 graphicRef78018 \" href=\"UTD.htm?5/55/6014\">",
"     table 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It may be possible to avoid IRIS by treating identified OIs that have an effective antimicrobial therapy (eg, PCP, tuberculosis, HBV, and cryptococcosis) for one to two months prior to initiation of HAART.",
"   </p>",
"   <p>",
"    In such circumstances, antimicrobial therapy without concurrent immune reconstitution may reduce a high burden of organisms (and associated microbial antigens) thus decreasing the risk of IRIS when HAART is subsequently initiated. Randomized controlled trials in addition to the trial done in Uganda cited above [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/57\">",
"     57",
"    </a>",
"    ] designed to test this hypothesis for several specific infectious agents are currently underway.",
"   </p>",
"   <p>",
"    A retrospective cohort study found an increased risk of death and opportunistic infections during the first two months of antituberculous therapy in patients with MTb who were treated without HAART, particularly when the CD4 cell count was less than 100",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/48\">",
"     48",
"    </a>",
"    ]. Therefore, while awaiting additional evidence and in the hope of minimizing both the risk of IRIS and the risk of death and other OIs, we recommend only delaying HAART for about two weeks in patients with MTb and a CD4 cell count below 100",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"    HAART may be delayed two months in patients being treated for MTb who have a CD4 cell count above 100",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    so as to decrease the risk of IRIS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/123\">",
"     123",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17272?source=see_link\">",
"     \"Monitoring the HIV-infected patient on antituberculous medications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We believe it is best to promptly initiate HAART in patients with OIs that lack proven effective therapies other than HAART (eg, PML), despite the risk of an adverse outcome. To our knowledge there are no data showing that steroid therapy should routinely precede HAART in such cases, thus we normally do not use steroids unless or until symptoms of IRIS appear.",
"   </p>",
"   <p>",
"    In patients with hepatitis B virus (HBV) infection, we and others recommend that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    may be included in the HAART regimen in order to simultaneously attain and maintain HIV and HBV viral suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?22/35/23098/abstract/124\">",
"     124",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A directed history and physical should be performed looking for evidence of OIs such as symptoms of MAC, prior to initiating HAART in patients with low CD4 cell counts. Additional diagnostic testing should be performed if the examination suggests an OI may be present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of each individual case of IRIS are highly variable and data from controlled trials have not been published thus far to provide clear guidelines. Our recommendations are based on clinical experience, case reports, case series, and expert opinion:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although it is reasonable to perform studies looking for unmasked subclinical opportunistic infection, the diagnosis of IRIS is generally one of exclusion. Investigations to rule out the possibility of drug reaction, patient noncompliance, persistently active infection",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      drug resistance are usually warranted before concluding that IRIS is present.",
"     </li>",
"     <li>",
"      Most patients with IRIS develop symptoms within one week to a few months after the initiation of HAART. With later onset, other diagnoses become more likely.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       Abacavir",
"      </a>",
"      hypersensitivity can be confused with IRIS, but symptoms worsen soon after each dose of abacavir. The diagnostic work-up for abacavir hypersensitivity reaction includes genetic testing for HLA-B5701.",
"     </li>",
"     <li>",
"      When a diagnosis of IRIS is considered highly likely, further or repeated invasive diagnostic procedures to locate an occult infection may be reasonably delayed, deferred, or altogether avoided.",
"     </li>",
"     <li>",
"      Treatment for the underlying pathogen should generally be started or continued in patients who develop IRIS. This is particularly important when treating patients with IRIS associated with hepatitis B virus.",
"     </li>",
"     <li>",
"      Corticosteroids or NSAIDS may help decrease the inflammatory response in some patients with IRIS. The decision to use corticosteroids should be individualized and should take into account the risks of therapy. When we choose to treat with corticosteroids, we initiate therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      at a dose of 1",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      (maximal dose 60 to 80 mg) and then taper steroid therapy while monitoring for recurrence of clinical symptoms over the ensuing weeks to months.",
"     </li>",
"     <li>",
"      We suggest initiation of ART within two weeks of starting treatment of the underlying opportunistic infection to decrease the risk of clinical progression of AIDS and death. The treatment of the HIV-infected patient with tuberculosis is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17272?source=see_link\">",
"       \"Monitoring the HIV-infected patient on antituberculous medications\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For OIs that lack proven effective therapies other than HAART (eg, PML), we believe it is best to treat these patients with HAART despite the risk of an adverse outcome. We normally do not use steroids in such patients unless or until symptoms of IRIS appear.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/1\">",
"      DeSimone JA, Pomerantz RJ, Babinchak TJ. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med 2000; 133:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/2\">",
"      French MA, Lenzo N, John M, et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med 2000; 1:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/3\">",
"      Shelburne SA 3rd, Hamill RJ, Rodriguez-Barradas MC, et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 2002; 81:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/4\">",
"      Michelet C, Arvieux C, Fran&ccedil;ois C, et al. Opportunistic infections occurring during highly active antiretroviral treatment. AIDS 1998; 12:1815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/5\">",
"      Hirsch HH, Kaufmann G, Sendi P, Battegay M. Immune reconstitution in HIV-infected patients. Clin Infect Dis 2004; 38:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/6\">",
"      Shelburne SA, Montes M, Hamill RJ. Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother 2006; 57:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/7\">",
"      French MA. HIV/AIDS: immune reconstitution inflammatory syndrome: a reappraisal. Clin Infect Dis 2009; 48:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/8\">",
"      Cheng VC, Yuen KY, Chan WM, et al. Immunorestitution disease involving the innate and adaptive response. Clin Infect Dis 2000; 30:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/9\">",
"      Cooney EL. Clinical indicators of immune restoration following highly active antiretroviral therapy. Clin Infect Dis 2002; 34:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/10\">",
"      Campbell IA, Dyson AJ. Lymph node tuberculosis: a comparison of various methods of treatment. Tubercle 1977; 58:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/11\">",
"      Chambers ST, Hendrickse WA, Record C, et al. Paradoxical expansion of intracranial tuberculomas during chemotherapy. Lancet 1984; 2:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/12\">",
"      Smith H. Paradoxical responses during the chemotherapy of tuberculosis. J Infect 1987; 15:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/13\">",
"      Garcia Vidal C, Rodr&iacute;guez Fern&aacute;ndez S, Mart&iacute;nez Lacasa J, et al. Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis 2005; 40:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/14\">",
"      Sansonetti P, Lagrange PH. The immunology of leprosy: speculations on the leprosy spectrum. Rev Infect Dis 1981; 3:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/15\">",
"      Singh N, Lortholary O, Alexander BD, et al. An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin Infect Dis 2005; 40:1756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/16\">",
"      Cadena J, Thompson GR 3rd, Ho TT, et al. Immune reconstitution inflammatory syndrome after cessation of the tumor necrosis factor alpha blocker adalimumab in cryptococcal pneumonia. Diagn Microbiol Infect Dis 2009; 64:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/17\">",
"      Pakker NG, Notermans DW, de Boer RJ, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 1998; 4:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/18\">",
"      Notermans DW, Pakker NG, Hamann D, et al. Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults. J Infect Dis 1999; 180:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/19\">",
"      Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/20\">",
"      Markert ML, Alvarez-McLeod AP, Sempowski GD, et al. Thymopoiesis in HIV-infected adults after highly active antiretroviral therapy. AIDS Res Hum Retroviruses 2001; 17:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/21\">",
"      Franco JM, Rubio A, Mart&iacute;nez-Moya M, et al. T-cell repopulation and thymic volume in HIV-1-infected adult patients after highly active antiretroviral therapy. Blood 2002; 99:3702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/22\">",
"      Sempowski GD, Haynes BF. Immune reconstitution in patients with HIV infection. Annu Rev Med 2002; 53:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/23\">",
"      Lederman MM, Connick E, Landay A, et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis 1998; 178:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/24\">",
"      Antonelli LR, Mahnke Y, Hodge JN, et al. Elevated frequencies of highly activated CD4+ T cells in HIV+ patients developing immune reconstitution inflammatory syndrome. Blood 2010; 116:3818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/25\">",
"      Haddow LJ, Easterbrook PJ, Mosam A, et al. Defining immune reconstitution inflammatory syndrome: evaluation of expert opinion versus 2 case definitions in a South African cohort. Clin Infect Dis 2009; 49:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/26\">",
"      Grant PM, Komarow L, Andersen J, et al. Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. PLoS One 2010; 5:e11416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/27\">",
"      Ratnam I, Chiu C, Kandala NB, Easterbrook PJ. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis 2006; 42:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/28\">",
"      Manabe YC, Campbell JD, Sydnor E, Moore RD. Immune reconstitution inflammatory syndrome: risk factors and treatment implications. J Acquir Immune Defic Syndr 2007; 46:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/29\">",
"      Jabs DA, Van Natta ML, Kempen JH, et al. Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Am J Ophthalmol 2002; 133:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/30\">",
"      Breton G, Duval X, Estellat C, et al. Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis 2004; 39:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/31\">",
"      Murdoch DM, Venter WD, Feldman C, Van Rie A. Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. AIDS 2008; 22:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/32\">",
"      M&uuml;ller M, Wandel S, Colebunders R, et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/33\">",
"      Nolan RC, Chidlow G, French MA. Parvovirus B19 encephalitis presenting as immune restoration disease after highly active antiretroviral therapy for human immunodeficiency virus infection. Clin Infect Dis 2003; 36:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/34\">",
"      Breton G, Adle-Biassette H, Therby A, et al. Immune reconstitution inflammatory syndrome in HIV-infected patients with disseminated histoplasmosis. AIDS 2006; 20:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/35\">",
"      van Hal SJ, Kotsiou G. An HIV-positive man with generalized rash. Clin Infect Dis 2005; 40:113, 182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/36\">",
"      Couppi&eacute; P, Abel S, Voinchet H, et al. Immune reconstitution inflammatory syndrome associated with HIV and leprosy. Arch Dermatol 2004; 140:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/37\">",
"      Lawn SD, Wood C, Lockwood DN. Borderline tuberculoid leprosy: an immune reconstitution phenomenon in a human immunodeficiency virus-infected person. Clin Infect Dis 2003; 36:e5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/38\">",
"      Menezes VM, Sales AM, Illarramendi X, et al. Leprosy reaction as a manifestation of immune reconstitution inflammatory syndrome: a case series of a Brazilian cohort. AIDS 2009; 23:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/39\">",
"      Puthanakit T, Oberdorfer P, Punjaisee S, et al. Immune reconstitution syndrome due to bacillus Calmette-Gu&eacute;rin after initiation of antiretroviral therapy in children with HIV infection. Clin Infect Dis 2005; 41:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/40\">",
"      Gupta S, Mathur P, Maskey D, et al. Immune restoration syndrome with disseminated Penicillium marneffei and cytomegalovirus co-infections in an AIDS patient. AIDS Res Ther 2007; 4:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/41\">",
"      de Silva S, Walsh J, Brown M. Symptomatic Schistosoma mansoni infection as an immune restoration phenomenon in a patient receiving antiretroviral therapy. Clin Infect Dis 2006; 42:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/42\">",
"      Shelburne SA, Visnegarwala F, Darcourt J, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005; 19:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/43\">",
"      Connick E, Kane MA, White IE, et al. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma during potent antiretroviral therapy. Clin Infect Dis 2004; 39:1852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/44\">",
"      Bower M, Nelson M, Young AM, et al. Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma. J Clin Oncol 2005; 23:5224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/45\">",
"      Cheng VC, Ho PL, Lee RA, et al. Clinical spectrum of paradoxical deterioration during antituberculosis therapy in non-HIV-infected patients. Eur J Clin Microbiol Infect Dis 2002; 21:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/46\">",
"      Manabe YC, Breen R, Perti T, et al. Unmasked tuberculosis and tuberculosis immune reconstitution inflammatory disease: a disease spectrum after initiation of antiretroviral therapy. J Infect Dis 2009; 199:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/47\">",
"      Hawkey CR, Yap T, Pereira J, et al. Characterization and management of paradoxical upgrading reactions in HIV-uninfected patients with lymph node tuberculosis. Clin Infect Dis 2005; 40:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/48\">",
"      Dheda K, Lampe FC, Johnson MA, Lipman MC. Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis 2004; 190:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/49\">",
"      Matthay RA, Neff TA, Iseman MD. Tuberculous pleural effusions developing during chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1974; 109:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/50\">",
"      Al-Majed SA. Study of paradoxical response to chemotherapy in tuberculous pleural effusion. Respir Med 1996; 90:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/51\">",
"      Price P, Murdoch DM, Agarwal U, et al. Immune restoration diseases reflect diverse immunopathological mechanisms. Clin Microbiol Rev 2009; 22:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/52\">",
"      Afghani B, Lieberman JM. Paradoxical enlargement or development of intracranial tuberculomas during therapy: case report and review. Clin Infect Dis 1994; 19:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/53\">",
"      Nicolls DJ, King M, Holland D, et al. Intracranial tuberculomas developing while on therapy for pulmonary tuberculosis. Lancet Infect Dis 2005; 5:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/54\">",
"      Pepper DJ, Marais S, Maartens G, et al. Neurologic manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome: a case series. Clin Infect Dis 2009; 48:e96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/55\">",
"      Rooney JJ Jr, Crocco JA, Kramer S, Lyons HA. Further observations on tuberculin reactions in active tuberculosis. Am J Med 1976; 60:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/56\">",
"      Dooley DP, Carpenter JL, Rademacher S. Adjunctive corticosteroid therapy for tuberculosis: a critical reappraisal of the literature. Clin Infect Dis 1997; 25:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/57\">",
"      Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/58\">",
"      Chien JW, Johnson JL. Paradoxical reactions in HIV and pulmonary TB. Chest 1998; 114:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/59\">",
"      John M, French MA. Exacerbation of the inflammatory response to Mycobacterium tuberculosis after antiretroviral therapy. Med J Aust 1998; 169:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/60\">",
"      Navas E, Mart&iacute;n-D&aacute;vila P, Moreno L, et al. Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy. Arch Intern Med 2002; 162:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/61\">",
"      Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998; 158:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/62\">",
"      Fishman JE, Saraf-Lavi E, Narita M, et al. Pulmonary tuberculosis in AIDS patients: transient chest radiographic worsening after initiation of antiretroviral therapy. AJR Am J Roentgenol 2000; 174:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/63\">",
"      Kumarasamy N, Chaguturu S, Mayer KH, et al. Incidence of immune reconstitution syndrome in HIV/tuberculosis-coinfected patients after initiation of generic antiretroviral therapy in India. J Acquir Immune Defic Syndr 2004; 37:1574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/64\">",
"      Hill AR, Mateo F, Hudak A. Transient exacerbation of tuberculous lymphadenitis during chemotherapy in patients with AIDS. Clin Infect Dis 1994; 19:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/65\">",
"      Furrer H, Malinverni R. Systemic inflammatory reaction after starting highly active antiretroviral therapy in AIDS patients treated for extrapulmonary tuberculosis. Am J Med 1999; 106:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/66\">",
"      Guex AC, Bucher HC, Demartines N, et al. Inflammatory bowel perforation during immune restoration after one year of antiretroviral and antituberculous therapy in an HIV-1-infected patient: report of a case. Dis Colon Rectum 2002; 45:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/67\">",
"      Jehle AW, Khanna N, Sigle JP, et al. Acute renal failure on immune reconstitution in an HIV-positive patient with miliary tuberculosis. Clin Infect Dis 2004; 38:e32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/68\">",
"      Cabi&eacute; A, Abel S, Brebion A, et al. Mycobacterial lymphadenitis after initiation of highly active antiretroviral therapy. Eur J Clin Microbiol Infect Dis 1998; 17:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/69\">",
"      Race EM, Adelson-Mitty J, Kriegel GR, et al. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet 1998; 351:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/70\">",
"      Phillips P, Bonner S, Gataric N, et al. Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up. Clin Infect Dis 2005; 41:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/71\">",
"      Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005; 5:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/72\">",
"      Dworkin MS, Fratkin MD. Mycobacterium avium complex lymph node abscess after use of highly active antiretroviral therapy in a patient with AIDS. Arch Intern Med 1998; 158:1828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/73\">",
"      Murray R, Mallal S, Heath C, French M. Cerebral mycobacterium avium infection in an HIV-infected patient following immune reconstitution and cessation of therapy for disseminated mycobacterium avium complex infection. Eur J Clin Microbiol Infect Dis 2001; 20:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/74\">",
"      Cinti SK, Kaul DR, Sax PE, et al. Recurrence of Mycobacterium avium infection in patients receiving highly active antiretroviral therapy and antimycobacterial agents. Clin Infect Dis 2000; 30:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/75\">",
"      Hill AR, Premkumar S, Brustein S, et al. Disseminated tuberculosis in the acquired immunodeficiency syndrome era. Am Rev Respir Dis 1991; 144:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/76\">",
"      Skiest DJ, Hester LJ, Hardy RD. Cryptococcal immune reconstitution inflammatory syndrome: report of four cases in three patients and review of the literature. J Infect 2005; 51:e289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/77\">",
"      Lortholary O, Fontanet A, M&eacute;main N, et al. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS 2005; 19:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/78\">",
"      Sungkanuparph S, Jongwutiwes U, Kiertiburanakul S. Timing of cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in patients with AIDS and cryptococcal meningitis. J Acquir Immune Defic Syndr 2007; 45:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/79\">",
"      Woods ML 2nd, MacGinley R, Eisen DP, Allworth AM. HIV combination therapy: partial immune restitution unmasking latent cryptococcal infection. AIDS 1998; 12:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/80\">",
"      Boulware DR, Bonham SC, Meya DB, et al. Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome. J Infect Dis 2010; 202:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/81\">",
"      Shelburne SA 3rd, Darcourt J, White AC Jr, et al. The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 40:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/82\">",
"      Singh N, Perfect JR. Immune reconstitution syndrome associated with opportunistic mycoses. Lancet Infect Dis 2007; 7:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/83\">",
"      Jenny-Avital ER, Abadi M. Immune reconstitution cryptococcosis after initiation of successful highly active antiretroviral therapy. Clin Infect Dis 2002; 35:e128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/84\">",
"      Blanche P, Gombert B, Ginsburg C, et al. HIV combination therapy: immune restitution causing cryptococcal lymphadenitis dramatically improved by anti-inflammatory therapy. Scand J Infect Dis 1998; 30:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/85\">",
"      Wright ME, Suzman DL, Csaky KG, et al. Extensive retinal neovascularization as a late finding in human immunodeficiency virus-infected patients with immune recovery uveitis. Clin Infect Dis 2003; 36:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/86\">",
"      Karavellas MP, Plummer DJ, Macdonald JC, et al. Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy. J Infect Dis 1999; 179:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/87\">",
"      Wohl DA, Kendall MA, Owens S, et al. The safety of discontinuation of maintenance therapy for cytomegalovirus (CMV) retinitis and incidence of immune recovery uveitis following potent antiretroviral therapy. HIV Clin Trials 2005; 6:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/88\">",
"      Jacobson MA, Zegans M, Pavan PR, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997; 349:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/89\">",
"      Karavellas MP, Song M, Macdonald JC, Freeman WR. Long-term posterior and anterior segment complications of immune recovery uveitis associated with cytomegalovirus retinitis. Am J Ophthalmol 2000; 130:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/90\">",
"      Miller RF, Shaw PJ, Williams IG. Immune reconstitution CMV pneumonitis. Sex Transm Infect 2000; 76:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/91\">",
"      Gilquin J, Piketty C, Thomas V, et al. Acute cytomegalovirus infection in AIDS patients with CD4 counts above 100 x 10(6) cells/l following combination antiretroviral therapy including protease inhibitors. AIDS 1997; 11:1659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/92\">",
"      Gallant JE, Moore RD, Richman DD, et al. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. J Infect Dis 1992; 166:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/93\">",
"      Cinque P, Bossolasco S, Brambilla AM, et al. The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: study of 43 cases with review of the literature. J Neurovirol 2003; 9 Suppl 1:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/94\">",
"      Collazos J, Mayo J, Mart&iacute;nez E, Blanco MS. Contrast-enhancing progressive multifocal leukoencephalopathy as an immune reconstitution event in AIDS patients. AIDS 1999; 13:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/95\">",
"      Berenguer J, Miralles P, Arrizabalaga J, et al. Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. Clin Infect Dis 2003; 36:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/96\">",
"      Hoffmann C, Horst HA, Albrecht H, Schlote W. Progressive multifocal leucoencephalopathy with unusual inflammatory response during antiretroviral treatment. J Neurol Neurosurg Psychiatry 2003; 74:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/97\">",
"      Vendrely A, Bienvenu B, Gasnault J, et al. Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy. Acta Neuropathol 2005; 109:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/98\">",
"      Safdar A, Rubocki RJ, Horvath JA, et al. Fatal immune restoration disease in human immunodeficiency virus type 1-infected patients with progressive multifocal leukoencephalopathy: impact of antiretroviral therapy-associated immune reconstitution. Clin Infect Dis 2002; 35:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/99\">",
"      Barry SM, Lipman MC, Deery AR, et al. Immune reconstitution pneumonitis following Pneumocystis carinii pneumonia in HIV-infected subjects. HIV Med 2002; 3:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/100\">",
"      Koval CE, Gigliotti F, Nevins D, Demeter LM. Immune reconstitution syndrome after successful treatment of Pneumocystis carinii pneumonia in a man with human immunodeficiency virus type 1 infection. Clin Infect Dis 2002; 35:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/101\">",
"      Wislez M, Bergot E, Antoine M, et al. Acute respiratory failure following HAART introduction in patients treated for Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 2001; 164:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/102\">",
"      Mart&iacute;nez E, Gatell J, Mor&aacute;n Y, et al. High incidence of herpes zoster in patients with AIDS soon after therapy with protease inhibitors. Clin Infect Dis 1998; 27:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/103\">",
"      Carr A, Cooper DA. Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor. Lancet 1997; 349:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/104\">",
"      Drake A, Mijch A, Sasadeusz J. Immune reconstitution hepatitis in HIV and hepatitis B coinfection, despite lamivudine therapy as part of HAART. Clin Infect Dis 2004; 39:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/105\">",
"      John M, Flexman J, French MA. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? AIDS 1998; 12:2289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/106\">",
"      Rutschmann OT, Negro F, Hirschel B, et al. Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV. J Infect Dis 1998; 177:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/107\">",
"      Zylberberg H, Pialoux G, Carnot F, et al. Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy. Clin Infect Dis 1998; 27:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/108\">",
"      Monsuez JJ, Vittecoq D, Musset L, et al. Arthralgias and cryoglobulinemia during protease inhibitor therapy in a patient infected with human immunodeficiency virus and hepatitis C virus. Arthritis Rheum 1998; 41:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/109\">",
"      Posada-Vergara MP, Lindoso JA, Tolezano JE, et al. Tegumentary leishmaniasis as a manifestation of immune reconstitution inflammatory syndrome in 2 patients with AIDS. J Infect Dis 2005; 192:1819.",
"     </a>",
"    </li>",
"    <li>",
"     Clutter D, Kambugu A, Orem J, et al. Kaposi's Sarcoma-associated IRIS in Africa: Initial findings from a prospective evaluation. Presented at the 16th Annual Conference on Retroviruses and Opportunistic Infections, Montreal, Canada February 8-11th, 2009; abstract #31.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/111\">",
"      Crane HM, Deubner H, Huang JC, et al. Fatal Kaposi's sarcoma-associated immune reconstitution following HAART initiation. Int J STD AIDS 2005; 16:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/112\">",
"      Achenbach CJ, Harrington RD, Dhanireddy S, et al. Paradoxical immune reconstitution inflammatory syndrome in HIV-infected patients treated with combination antiretroviral therapy after AIDS-defining opportunistic infection. Clin Infect Dis 2012; 54:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/113\">",
"      Gomez V, Smith PR, Burack J, et al. Sarcoidosis after antiretroviral therapy in a patient with acquired immunodeficiency syndrome. Clin Infect Dis 2000; 31:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/114\">",
"      Lenner R, Bregman Z, Teirstein AS, DePalo L. Recurrent pulmonary sarcoidosis in HIV-infected patients receiving highly active antiretroviral therapy. Chest 2001; 119:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/115\">",
"      Naccache JM, Antoine M, Wislez M, et al. Sarcoid-like pulmonary disorder in human immunodeficiency virus-infected patients receiving antiretroviral therapy. Am J Respir Crit Care Med 1999; 159:2009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/116\">",
"      Gilquin J, Viard JP, Jubault V, et al. Delayed occurrence of Graves' disease after immune restoration with HAART. Highly active antiretroviral therapy. Lancet 1998; 352:1907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/117\">",
"      Jubault V, Penfornis A, Schillo F, et al. Sequential occurrence of thyroid autoantibodies and Graves' disease after immune restoration in severely immunocompromised human immunodeficiency virus-1-infected patients. J Clin Endocrinol Metab 2000; 85:4254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/118\">",
"      Chen F, Day SL, Metcalfe RA, et al. Characteristics of autoimmune thyroid disease occurring as a late complication of immune reconstitution in patients with advanced human immunodeficiency virus (HIV) disease. Medicine (Baltimore) 2005; 84:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/119\">",
"      Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One 2009; 4:e5575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/120\">",
"      Castelnuovo B, Manabe YC, Kiragga A, et al. Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort. Clin Infect Dis 2009; 49:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/121\">",
"      Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304:321.",
"     </a>",
"    </li>",
"    <li>",
"     file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&amp;Search=Off&amp;GuidelineID=7&amp;ClassID=1 (Accessed on September 20, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/123\">",
"      Burman WJ. Issues in the management of HIV-related tuberculosis. Clin Chest Med 2005; 26:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/35/23098/abstract/124\">",
"      McGovern B. What drives hepatitis B virus-related hepatic flares? Virus, T cells--or a bit of both? Clin Infect Dis 2004; 39:133.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3762 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-221.10.40.232-29E1B55F6D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_35_23098=[""].join("\n");
var outline_f22_35_23098=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      IMMUNOBIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSTIC CRITERIA FOR IRIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2253293\">",
"      PATHOGENS ASSOCIATED WITH IRIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      IRIS associated with mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      IRIS associated with preexisting cryptococcal infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      IRIS associated with cytomegalovirus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      IRIS due to preexisting infection with JC virus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      IRIS associated with Pneumocystis jirovecii infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      IRIS associated with herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      IRIS associated with hepatitis B and C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Leishmaniasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Kaposi sarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Miscellaneous syndromes possibly associated with IRIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Timing of antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Options for management of IRIS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Continuation of ART when IRIS occurs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Role of anti-inflammatory agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3762\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3762|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/16/19717\" title=\"diagnostic image 1\">",
"      CT enlarged lymph node",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3762|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/44/42688\" title=\"picture 1\">",
"      Left neck lymphodenopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/61/11216\" title=\"picture 2\">",
"      Endobronchial lesion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3762|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/24/4493\" title=\"table 1A\">",
"      Management IRIS A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/53/35676\" title=\"table 1B\">",
"      Management IRIS B",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/37/18009?source=related_link\">",
"      AIDS-related Kaposi sarcoma: Staging and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21049?source=related_link\">",
"      Abacavir hypersensitivity reaction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/2/28713?source=related_link\">",
"      Central nervous system tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/7/44151?source=related_link\">",
"      Clinical manifestations and diagnosis of JC, BK, and other polyomavirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7033?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30218?source=related_link\">",
"      Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/34/5674?source=related_link\">",
"      Immunology of HIV-1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17272?source=related_link\">",
"      Monitoring the HIV-infected patient on antituberculous medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27593?source=related_link\">",
"      Treatment of Pneumocystis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16185?source=related_link\">",
"      Treatment of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/38/18026?source=related_link\">",
"      Treatment of hepatitis C virus infection in the HIV-infected patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_35_23099="Wheat alternatives";
var content_f22_35_23099=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F54072&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F54072&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Nutrients to be replaced on a wheat avoidance diet and alternative dietary sources",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Nutrients in wheat",
"      </td>",
"      <td class=\"subtitle1\">",
"       Alternative dietary sources",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Carbohydrates",
"      </td>",
"      <td>",
"       Products made with alternative grains or flours: rice, oat, corn, buckwheat, potato, tapioca, chickpea, amaranth, millet, quinoa; fruits and vegetables",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fiber",
"      </td>",
"      <td>",
"       Fruits, vegetables, alternative whole grains",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Niacin (vitamin B3)",
"      </td>",
"      <td>",
"       Meat, fish, poultry, liver, peanuts, sunflower seeds, legumes, enriched and whole grain alternative grain products",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Thiamine (vitamin B1)",
"      </td>",
"      <td>",
"       Liver, pork, other meats, sunflower seeds, enriched and whole grain alternative grain products, nuts and legumes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Riboflavin",
"      </td>",
"      <td>",
"       Milk, dark green leafy vegetables, enriched and whole grain alternative grain products",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Iron",
"      </td>",
"      <td>",
"       <p>",
"        Heme iron: Meat, fish, shellfish, poultry",
"       </p>",
"       <p>",
"        Non-heme irons: Enriched and whole grain alternative grain products, legumes and dried fruits",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Folic acid",
"      </td>",
"      <td>",
"       Enriched and whole grain alternative grain products, beef liver, green leafy vegetables, legumes, seeds, orange juice",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_35_23099=[""].join("\n");
var outline_f22_35_23099=null;
var title_f22_35_23100="Efficacy of treatment in HPS";
var content_f22_35_23100=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52526&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52526&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Categories of treatment of the hepatopulmonary syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Treatment",
"       </td>",
"       <td class=\"subtitle1\">",
"        Efficacy for improving gas exchange in the hepatopulmonary syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Physically occlude IPVDs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Spring coil embolization",
"       </td>",
"       <td>",
"        Modest if technically possible",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Oppose circulating vasodilators",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Octreotide (somatostatin analog)",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nitric oxide synthase inhibitors",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Indomethacin",
"       </td>",
"       <td>",
"        Poor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Improve V/Q matching",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Almitrine bismesylate",
"       </td>",
"       <td>",
"        Slight",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Treat underlying liver disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chemotherapy and corticosteroids",
"       </td>",
"       <td>",
"        Helpful in one patient",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Liver transplantation",
"       </td>",
"       <td>",
"        Moderately good but variable response",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Treat portal hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        TIPS (transjugular intrahepatic portosystemic shunt)",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Other (miscellaneous)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methylene blue",
"       </td>",
"       <td>",
"        Variable in the few patients described",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Allium sativum (garlic)",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Propranolol",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Plasma exchange",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sympathomimetics",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Lange PA, Stoller JK, Ann Intern Med 1995; 122:521.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_35_23100=[""].join("\n");
var outline_f22_35_23100=null;
var title_f22_35_23101="Exchange system menu PI";
var content_f22_35_23101=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F70878&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F70878&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sample exchange system meal plan",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Time",
"       </td>",
"       <td class=\"subtitle1\">",
"        Exchange pattern",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sample menu",
"       </td>",
"       <td class=\"subtitle1\">",
"        Carbohydrate count (g)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        8 am",
"       </td>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        3 carbohydrate group",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2 starch",
"       </td>",
"       <td class=\"sublist_other\">",
"        1 English muffin",
"       </td>",
"       <td class=\"sublist_other\">",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1 fruit",
"       </td>",
"       <td class=\"sublist_other\">",
"        1 1/4 c strawberries",
"       </td>",
"       <td class=\"sublist_other\">",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 protein group",
"       </td>",
"       <td>",
"        1/4 c cottage cheese",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 fat group",
"       </td>",
"       <td>",
"        1 tsp margarine",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Total: 45",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"7\">",
"        12 noon",
"       </td>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        4 carbohydrate group",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2 starch",
"       </td>",
"       <td class=\"sublist_other\">",
"        2 slices of bread",
"       </td>",
"       <td class=\"sublist_other\">",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1 fruit",
"       </td>",
"       <td class=\"sublist_other\">",
"        1 orange",
"       </td>",
"       <td class=\"sublist_other\">",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1 vegetable",
"       </td>",
"       <td class=\"sublist_other\">",
"        1 c salad",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1 milk",
"       </td>",
"       <td class=\"sublist_other\">",
"        8 oz skim milk",
"       </td>",
"       <td class=\"sublist_other\">",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3 protein group",
"       </td>",
"       <td>",
"        3 oz chicken",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 fat group",
"       </td>",
"       <td>",
"        1 tbsp low fat mayo",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Total: 57",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        3 pm",
"       </td>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        1 carbohydrate group",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1 fruit or 1 starch",
"       </td>",
"       <td class=\"sublist_other\">",
"        1 apple or 6 crackers",
"       </td>",
"       <td class=\"sublist_other\">",
"        15",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Total: 15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"7\">",
"        6 pm",
"       </td>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        4 carbohydrate group",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2 starch",
"       </td>",
"       <td class=\"sublist_other\">",
"        1 c potato",
"       </td>",
"       <td class=\"sublist_other\">",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1 fruit",
"       </td>",
"       <td class=\"sublist_other\">",
"        1/2 c fruit salad",
"       </td>",
"       <td class=\"sublist_other\">",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1 vegetable",
"       </td>",
"       <td class=\"sublist_other\">",
"        1 c salad",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1 milk",
"       </td>",
"       <td class=\"sublist_other\">",
"        8 oz skim milk",
"       </td>",
"       <td class=\"sublist_other\">",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6 protein group",
"       </td>",
"       <td>",
"        6 oz fish",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 fat group",
"       </td>",
"       <td>",
"        2 tbsp low fat salad dressing",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        <strong>",
"         Total: 57",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        9 pm",
"       </td>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        1 carbohydrate group",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1 starch",
"       </td>",
"       <td class=\"sublist_other\">",
"        6 crackers",
"       </td>",
"       <td class=\"sublist_other\">",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 protein",
"       </td>",
"       <td>",
"        2 tbsp peanut butter",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        <strong>",
"         Total: 15",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_35_23101=[""].join("\n");
var outline_f22_35_23101=null;
var title_f22_35_23102="Proposed modified gluten challenge algorithm";
var content_f22_35_23102=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F85570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F85570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 508px\">",
"   <div class=\"ttl\">",
"    Proposed modified gluten challenge algorithm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 488px; height: 404px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Gut, Leffler D, Schuppan D, Pallav K, et al. Kinetics of the histological, serological and symptomatic responses to gluten challenge in adults with coeliac disease. Copyright &copy; 2012, with permission from BMJ Publishing Group Ltd.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_35_23102=[""].join("\n");
var outline_f22_35_23102=null;
var title_f22_35_23103="India ink persistent staining";
var content_f22_35_23103=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F78733&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F78733&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 517px\">",
"   <div class=\"ttl\">",
"    India ink staining",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 497px; height: 204px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Persistent India ink staining is visible on colonoscopy two years after polypectomy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jerome D Waye, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_35_23103=[""].join("\n");
var outline_f22_35_23103=null;
